

ELECTRONIC SUPPLEMENTARY INFORMATION

3,4,5-Triarylisothiazoles *via* C-C Coupling Chemistry

Irene C. Christoforou and Panayiotis A. Koutentis*

Department of Chemistry, University of Cyprus, P.O. Box 20537, 1678 Nicosia,
Cyprus, koutenti@ucy.ac.cy

Experimental

CCl₄ and MeOH were freshly distilled from CaH₂ under argon. DMF was azeotropically distilled with PhH then distilled under vacuum from anhydrous MgSO₄ and stored over 4Å molecular sieves. THF was freshly distilled from potassium under argon. Anhydrous K₂CO₃ was freshly powdered using an agate pestle and mortar before use. Reactions were protected by CaCl₂ drying tubes or performed under an argon atmosphere. Anhydrous Na₂SO₄ was used for drying organic extracts, and all volatiles were removed under reduced pressure. All reaction mixtures and column eluents were monitored by TLC using commercial glass backed thin layer chromatography (TLC) plates (Merck Kieselgel 60 F₂₅₄). The plates were observed under UV light at 254 and 365 nm. The technique of dry flash chromatography was used throughout for all non-TLC scale chromatographic separations using Merck Silica Gel 60 (less than 0.063 mm). A Hastelloy B-2 Parr pressure vessel with a teflon sleeve and a 600 mL capacity (3000psi limit) was used for the autoclave reactions. Melting points were determined using a PolyTherm-A, Wagner & Munz, Koefler - Hotstage Microscope apparatus. Solvents used for recrystallization are indicated after the melting point. UV spectra were obtained using a Perkin-Elmer Lambda-25 UV/vis spectrophotometer and inflections are identified by the abbreviation “inf”. IR spectra were recorded on a Shimadzu FTIR-NIR Prestige-21 spectrometer with Pike *Miracle*

Ge ATR accessory and strong and medium peaks are represented by s and m respectively. ^1H and ^{13}C NMR spectra were recorded on a Bruker Avance 300 machine (at 300 and 75 MHz respectively). CH assignments were supported by ^{13}C NMR DEPT 90 experiments. Deuterated solvents were used for homonuclear lock and the signals are referenced to the deuterated solvent peaks. Low resolution (EI) mass spectra were recorded on a Shimadzu Q2010 GCMS with direct inlet probe whilst high resolution spectra were recorded on a VG Autospec “Q” mass spectrometer. Petrol refers to light petroleum, bp 40–60 °C. 3-Chloro-5-phenylisothiazole-4-carbonitrile **1**³⁰, 3-iodo-5-phenylisothiazole-4-carbonitrile **18**³¹ and 3,5-diphenylisothiazole-4-carbonitrile **26**³¹ were prepared according to literature procedures.

3-Chloro-5-phenylisothiazole-4-carboxamide **2**

A stirred solution of 3-chloro-5-phenylisothiazole-4-carbonitrile **1** (1.5 g, 6.82 mmol) in c. H_2SO_4 (25 ml) protected with CaCl_2 drying tube, was heated to *ca.* 100 °C until no starting material remained (TLC). The mixture was allowed to cool to *ca.* 20 °C and then was poured into ice-water to afford a white precipitate. The white precipitate was filtered, washed (H_2O) and dried under vacuum to give the *title compound* **2** (1.57 g, 97%) as colourless needles, mp 168–171 °C (from PhH); (Found: C, 50.4; H, 3.0; N, 11.6. $\text{C}_{10}\text{H}_7\text{ClN}_2\text{OS}$ requires C, 50.3; H, 3.0; N, 11.7%); $\lambda_{\max}(\text{DCM})/\text{nm}$ 269 (log ε 3.90); $\nu_{\max}/\text{cm}^{-1}$ 3380w (NH), 3184w (Ar CH), 1642s (C=O), 1618m, 1529w, 1491m, 1446w, 1403w, 1321w, 1295m, 1275m, 1103w, 1039m, 1018w, 1000w, 917w, 846m, 793w, 762m; δ_{H} (300 MHz; DMSO- d_6) 8.08 (1H, br s, NH), 7.80 (1H, br s, NH), 7.60–7.56 (2H, m, Ph CH), 7.49–7.46 (3H, m, Ph CH); δ_{C} (75 MHz; DMSO- d_6) 165.6, 163.6, 146.3, 129.5 (Ph CH), 128.8, 128.3 (Ph CH), 128.1, 126.7 (Ph CH); δ_{C} (75

MHz; DEPT 90, DMSO-d₆) 129.5 (Ph CH), 128.3 (Ph CH), 126.7 (Ph CH); *m/z* (EI) 240 (M⁺+2, 25%), 239 (M⁺+1, 44), 238 (M⁺, 68), 237 (M⁺-H, 100), 224 (27), 223 (13), 222 (72), 221 (13), 219 (3), 203 (M⁺-Cl, 4), 186 (3), 159 (12), 133 (18), 129 (11), 127 (15), 121 (4), 114 (4), 101 (4), 100 (3), 89 (18), 77 (13), 75 (5), 63 (6), 51 (10) (Found: M⁺, 237.9959, C₁₀H₇ClN₂OS requires *M*, 237.9968).

3-Chloro-5-phenylisothiazole-4-carboxylic acid 3

To a stirred solution of 3-chloro-5-phenylisothiazole-4-carboxamide **2** (1.5 g, 6.29 mmol) in c. H₂SO₄ (250 ml) cooled to *ca.* 0 °C and protected with CaCl₂ drying tube, was added in portions sodium nitrite (4.34 g, 62.9 mmol, 10 equiv.). The reaction mixture then was heated to *ca.* 100 °C, until no starting material remained (TLC). The mixture was allowed to cool to *ca.* 20 °C and was poured into ice-water to afford a white precipitate. The white precipitate was filtered out, washed (H₂O) and dried under vacuum to give the *title compound 3* (1.33 g, 88%) as colourless crystals, mp 162-164 °C (from cyclohexane); (Found: C, 50.0; H, 2.4; N, 5.7. C₁₀H₆ClNO₂S requires C, 50.1; H, 2.5; N, 5.8%); $\lambda_{\text{max}}(\text{DCM})/\text{nm}$ 268 (log ε 3.98); $\nu_{\text{max}}/\text{cm}^{-1}$ 2847br (OH), 1695s (C=O), 1517m, 1479m, 1436m, 1391m, 1345m, 1290w, 1283w, 1246m, 1221m, 1077w, 1043m, 1023w, 926w, 847m, 791w, 757w; δ_H(300 MHz; CD₂Cl₂) 10.72 (1H, br s, CO₂H), 7.54-7.45 (5H, m, Ph CH); δ_C(75 MHz; CD₂Cl₂) 175.3 (C=O), 166.4, 150.3, 131.0 (Ph CH), 129.4 (Ph C), 129.2 (Ph CH), 129.0 (Ph CH), 123.1; δ_C(75 MHz; DEPT 90, CD₂Cl₂) 131.0 (Ph CH), 129.2 (Ph CH), 129.0 (Ph CH); *m/z* (EI) 241 (M⁺+2, 37%), 240 (M⁺+1, 39), 239 (M⁺, 100), 238 (M⁺-1, 79), 224 (23), 222 (63), 204 (M⁺-Cl, 2), 186 (6), 176 (5), 159 (10), 133 (19), 129 (8), 127 (17), 121

(6), 114 (8), 100 (6), 89 (22), 77 (19), 63 (12), 51 (20) (Found: M⁺, 238.9803, C₁₀H₆ClNO₂S requires M, 238.9808).

4-Bromo-3-chloro-5-phenylisothiazole 5

To a stirred mixture of 3-chloro-5-phenylisothiazole-4-carboxylic acid **3** (1.0 g, 4.18 mmol) in H₂O (30 ml) was added a solution of KOH (234 mg, 4.18 mmol, 1 equiv.) in H₂O (10 ml) and the mixture was allowed to stirred at *ca.* 20 °C until the starting material had completely dissolved. To the reaction mixture was added, in one portion, a solution of silver nitrate (710 mg, 4.18 mmol, 1 equiv.) in H₂O (5 ml) to afford a grey-white precipitate. The grey-white precipitate was filtered, washed first with H₂O and then with acetone and dried in a vacuum oven at *ca.* 80 °C for 12 h to give silver 3-chloro-5-phenylisothiazole-4-carboxylate **4** (1.45 g, 100%). To a stirred mixture of silver 3-chloro-5-phenylisothiazole-4-carboxylate **4**, (100 mg, 0.29 mmol) in tetrachloromethane (3 ml) protected with CaCl₂ drying tube was added in one portion Br₂ (18 μ l, 0.35 mmol, 1.2 equiv.) and the reaction was kept at 20 °C for 1 h. The reaction mixture was filtered and the filtrate was absorbed on silica. Chromatography (hexane-DCM 8 : 2) gave the title compound **5** (63 mg, 80%) as colourless needles, mp 40-41 °C (lit.³⁴ 44-46 °C) (from pentane); (Found: C, 39.3; H, 1.9; N, 5.0. C₉H₅BrClNS requires C, 39.4; H, 1.8; N, 5.1%); $\lambda_{\text{max}}(\text{DCM})/\text{nm}$ 274 (log ε 3.91); $\nu_{\text{max}}/\text{cm}^{-1}$ 3049w (Ar CH), 1577w, 1559w, 1517w, 1507w, 1476m, 1457w, 1443m, 1388m, 1336w, 1313w, 1294s, 1278m, 1245w, 1217w, 1076w, 1032m, 996m, 920w, 901m, 819m; δ_{H} (300 MHz; CDCl₃) 7.67-7.60 (2H, m, Ph CH), 7.53-7.45 (3H, m, Ph CH); δ_{C} (75 MHz; CDCl₃) 163.4, 151.0, 130.4 (Ph CH), 129.3 (Ph C), 129.1 (Ph CH), 128.2 (Ph CH), 106.2; δ_{C} (75 MHz; DEPT 90, CDCl₃) 130.4 (Ph CH), 129.1 (Ph CH), 128.2 (Ph CH); *m/z* (EI) 277 (M⁺+4, 28%), 275 (M⁺+2, 100), 273 (M⁺, 58), 240 (4),

238 (4), 229 (7), 227 (5), 196 (5), 194 (14), 193 (4), 159 (50), 150 (4), 148 (4), 137 (3), 133 (17), 127 (29), 121 (6), 113 (11), 100 (10), 89 (18), 77 (11), 74 (10), 63 (12), 51 (19) (Found: M^+ , 272.9015, $C_9H_5BrClNS$ requires M , 272.9004).

4-Amino-3-chloro-5-phenylisothiazole 6

To a stirred solution of NaOH (42 mg, 1.05 mmol, 5 equiv.) in water (2 ml) cooled to *ca.* 0 °C was first added Br_2 (13 μ l, 0.25 mmol, 1.2 equiv.) and then 3-chloro-5-phenylisothiazole-4-carboxamide **2** (50 mg, 0.21 mmol). The reaction mixture was allowed to warm to *ca.* 20 °C and was kept at this temperature until the starting material had completely dissolved. The reaction mixture was then heated to *ca.* 70 °C for 1 h. The mixture was allowed to cool to *ca.* 20 °C, diluted with water (5 ml) and washed with DCM (4×10 ml). The organic layer was separated, dried and absorbed on silica. Chromatography (hexane-DCM, 5 : 5) gave the *title compound* **6** (36.7 mg, 83%) as colourless plates, mp 58-59 °C (from cyclohexane); (Found: C, 51.2; H, 3.2; N, 13.3. $C_9H_7ClN_2S$ requires C, 51.3; H, 3.4; N, 13.3%); λ_{max} (DCM)/nm 315 (log ε 2.79), 262 (2.66); ν_{max}/cm^{-1} 3373w and 3309w (NH_2), 3212w, 3061w (Ph CH), 1623w, 1576w, 1492w, 1445w, 1420m, 1374m, 1316w, 1282w, 1136w, 1086w, 1061w, 1027w, 994w, 974w, 926w, 823m, 764s; δ_H (300 MHz; $CDCl_3$) 7.50-7.37 (5H, m, Ph CH), 3.76 (2H, br s, NH_2); δ_C (75 MHz; $CDCl_3$) 140.8, 139.8, 134.0, 130.6 (Ph C), 129.5 (Ph CH), 128.8 (Ph CH), 127.1 (Ph CH); δ_C (75 MHz; DEPT 90, $CDCl_3$) 129.5 (Ph CH), 128.8 (Ph CH), 127.1 (Ph CH); m/z (EI) 212 (M^++2 , 31%), 210 (M^+ , 82), 175 (11), 148 (29), 142 (62), 121 (100), 104 (16), 93 (9), 89 (14), 77 (63), 69 (14), 63 (15), 62 (15), 53 (14), 51 (37).

3-Chloro-4-iodo-5-phenylisothiazole 7

To a stirred mixture of I₂ (90.5 mg, 0.358 mmol, 2.5 equiv.) and isoamyl nitrite (77 μ l, 0.573 mmol, 4 equiv.) in MeCN (2 ml) protected with CaCl₂ drying tube at *ca.* 80 °C was added dropwise an MeCN (1 ml) solution of 4-amino-3-chloro-5-phenylisothiazole **6** (30 mg, 0.143 mmol). The mixture was kept at *ca.* 80 °C until no starting material remained (TLC), allowed to cool to *ca.* 20 °C and absorbed on silica. Chromatography (hexane-DCM, 7 : 3) gave the *title compound* **7** (37.7 mg, 82%) as colourless needles, mp 67-68 °C (from pentane); (Found: C, 33.5; H, 1.5; N, 4.3. C₉H₅ClINS requires C, 33.6; H, 1.6; N, 4.4%); λ_{max} (DCM)/nm 275 (log ϵ 2.70); ν_{max} /cm⁻¹ 3046w (Ph CH), 1471m, 1442m, 1381m, 1335w, 1325w, 1286m, 1270s, 1238w, 1207w, 1077w, 1033m, 990m, 966w, 921w, 893m, 841w, 822m, 783w, 750s; δ_{H} (300 MHz; CDCl₃) 7.60-7.57 (2H, m, Ph CH), 7.53-7.51 (3H, m, Ph CH); δ_{C} (75 MHz; CDCl₃) 168.0, 154.5, 130.7 (Ph C), 130.4 (Ph CH), 129.1 (Ph CH), 128.5 (Ph CH), 79.5; δ_{C} (75 MHz; DEPT 90, CDCl₃) 130.4 (Ph CH), 129.1 (Ph CH), 128.5 (Ph CH); *m/z* (EI) 323 (M⁺+2, 36%), 321 (M⁺, 100), 194 (13), 159 (74), 148 (4), 133 (58), 127 (60), 121 (7), 113 (17), 100 (14), 89 (31), 77 (14), 75 (13), 74 (13), 73 (4), 69 (8), 63 (20), 51 (26).

3-Chloro-4,5-diphenylisothiazole **8 via Suzuki reaction at C-4**

A stirred mixture of 4-bromo-3-chloro-5-phenylisothiazole **5** (30 mg, 0.11 mmol), phenylboronic acid (40 mg, 0.33 mmol, 3 equiv.), powdered K₂CO₃ (22.8 mg, 0.165 mmol, 1.5 equiv.) and Pd(OAc)₂ (1.2 mg, 5 mol%) in dry and degassed DMF (2 ml) under an argon atmosphere, was heated to *ca.* 100 °C, until no starting material remained (TLC). The mixture was allowed to cool to *ca.* 20 °C, diluted with DCM (15 ml) and washed with H₂O (4 × 10 ml). The organic layer was separated, dried and absorbed on silica. Chromatography (hexane-DCM, 6 : 4) gave the *title compound* **8**

(28.7 mg, 96%) as colourless needles, mp 106-107 °C (from pentane); (Found: C, 66.4; H, 3.6; N, 5.2. $C_{15}H_{10}ClNS$ requires C, 66.3; H, 3.7; N, 5.2%); λ_{max} (DCM)/nm 275 (log ϵ 2.74); ν_{max}/cm^{-1} 3055w (Ar CH), 1599w, 1574w, 1537w, 1499w, 1477w, 1377w, 1346m, 1312w, 1236m, 1182w, 1143w, 1076w, 1034w, 995w, 988w, 920w, 907w, 843w, 833m, 802m, 770m, 748s, 710w, 694s; δ_H (300 MHz; $CDCl_3$) 7.44-7.22 (10H, m, Ph CH); δ_C (75 MHz; $CDCl_3$) 164.4, 150.0, 132.6, 131.8, 130.3 (Ph CH), 130.1 (Ph C), 129.5 (Ph CH), 128.9 (Ph CH), 128.6 (Ph CH), 128.3 (Ph CH), 128.2 (Ph CH); δ_C (75 MHz; DEPT 90, $CDCl_3$) 130.3 (Ph CH), 129.5 (Ph CH), 128.9 (Ph CH), 128.6 (Ph CH), 128.3 (Ph CH), 128.2 (Ph CH); m/z (EI) 273 ($M^{+}+2$, 34%), 271 (M^{+} , 100), 258 (7), 256 (19), 236 (27), 203 (30), 190 (20), 178 (12), 165 (13), 135 (3), 104 (15), 89 (4), 77 (15), 63 (4), 51 (10) (Found: M^{+} , 271.0207, $C_{15}H_{10}ClNS$ requires M , 271.0222).

3-Chloro-4,5-diphenylisothiazole 8 via Stille reaction at C-4 (typical Stille conditions for coupling at C-4: see Table 1)

A stirred mixture of 3-chloro-4-iodo-5-phenylisothiazole 7 (30 mg, 0.093 mmol), tributylphenylstannane (36.6 μ l, 0.112 mmol, 1.2 equiv.) and $Pd(OAc)_2$ (1.0 mg, 5 mol%) in dry and degassed DMF (2 ml) under an argon atmosphere, was heated to *ca.* 100 °C, until no starting material remained (TLC). The mixture was allowed to cool to *ca.* 20 °C, diluted with DCM (15 ml) and washed with H_2O (4 \times 10 ml). The organic layer was separated, dried and absorbed on silica. Chromatography (hexane-DCM, 6 : 4) gave the *title compound* 8 (25 mg, 99%) as colourless needles, mp 106-107 °C (from pentane) identical to that described above.

3-Chloro-5-phenyl-4-(thien-2-yl)isothiazole 9

Similar treatment of 3-chloro-4-iodo-5-phenylisothiazole **7** (30 mg, 0.093 mmol) with 2-(tributylstanny)thiophene and Pd(OAc)₂ gave the *title compound* **9** (25.8 mg, 100%) as colourless needles, mp 90-91 °C (from pentane); (Found: C, 56.2; H, 2.7; N, 5.0. C₁₃H₈ClNS₂ requires C, 56.2; H, 2.9; N, 5.0%); $\lambda_{\text{max}}(\text{DCM})/\text{nm}$ 251 (log ε 3.10), 274 inf (3.00); $\nu_{\text{max}}/\text{cm}^{-1}$ 3087w (Ar CH), 1486w, 1447w, 1431w, 1381w, 1364w, 1353w, 1326w, 1316w, 1306w, 1284w, 1238w, 1216w, 1221w, 1109w, 1077w, 1043w, 1031w, 984w, 967w, 927w, 882w, 852m, 821m, 779w, 759s; δ_{H} (300 MHz; CDCl₃) 7.41-7.28 (6H, m, Ar CH), 7.09-7.06 (2H, m, Ar CH); δ_{C} (75 MHz; CDCl₃) 165.5, 150.4, 131.7, 129.9, 129.9 (Ar CH), 129.3 (Ar CH), 129.0 (Ar CH), 128.3 (Ar CH), 127.5 (Ar CH), 127.2 (Ar CH), 126.1; δ_{C} (75 MHz; DEPT 90, CDCl₃) 129.9 (Ar CH), 129.3 (Ar CH), 129.0 (Ar CH), 128.3 (Ar CH), 127.5 (Ar CH), 127.2 (Ar CH); m/z (EI) 279 (M⁺+2, 41%), 277 (M⁺, 100), 264 (3), 262 (6), 244 (16), 242 (21), 241 (23), 234 (7), 232 (18), 209 (31), 208 (9), 196 (14), 184 (9), 171 (14), 164 (5), 139 (14), 121 (18), 107 (10), 93 (8), 77 (28), 69 (13), 63 (7), 51 (19).

3-Chloro-5-phenyl-4-(fur-2-yl)isothiazole 10

Similar treatment of 3-chloro-4-iodo-5-phenylisothiazole **7** (30 mg, 0.093 mmol) with 2-(tributylstanny)furan and Pd(OAc)₂ gave the *title compound* **10** (24.3 mg, 100%) as colourless needles, mp 71-72 °C (from pentane); (Found: C, 59.6; H, 3.2; N, 5.5. C₁₃H₈ClNOS requires C, 59.7; H, 3.1; N, 5.4%); $\lambda_{\text{max}}(\text{DCM})/\text{nm}$ 238 (log ε 3.00), 272 inf (2.79), 303 inf (2.70); $\nu_{\text{max}}/\text{cm}^{-1}$ 3146w, 3125w and 3060w (Ar CH), 1577w, 1517w, 1498w, 1464w, 1442w, 1397w, 1379w, 1338m, 1316w, 1256w, 1222w, 1172w, 1140w, 1078w, 1033w, 1022w, 996m, 948w, 920w, 887w, 876w, 830w, 822m, 790w, 757s, 711m; δ_{H} (300 MHz; CDCl₃) 7.46-7.36 (4H, m, Ar CH), 7.33-7.29 (2H, m, Ar CH), 6.64, (1H, app d, *J* 3.6, furyl H-3), 6.48 (1H, dd, *J* 3.4, 2.0, furyl H-

4); δ_{C} (75 MHz; CDCl₃) 165.6, 149.2, 144.7, 143.0 (Ar CH), 130.1 (Ar C), 129.9 (Ar CH), 128.9 (Ar CH), 128.2 (Ar CH), 123.1 (Ar C), 111.3 (Ar CH), 111.2 (Ar CH); δ_{C} (75 MHz; DEPT 90, CDCl₃) 143.0 (Ar CH), 129.9 (Ar CH), 128.9 (Ar CH), 128.2 (Ar CH), 111.3 (Ar CH), 111.2 (Ar CH); *m/z* (EI) 263 (M⁺+2, 37%), 261 (M⁺, 100), 236 (6), 234 (14), 226 (28), 208 (7), 198 (33), 196 (29), 193 (29), 171 (28), 153 (18), 139 (23), 127 (23), 121 (35), 104 (13), 99 (21), 95 (15), 93 (24), 85 (25), 77 (79), 69 (34), 63 (24), 51 (50).

3-Chloro-4,5-diphenylisothiazole 8 via Negishi reaction at C-4 position

A stirred mixture of 3-chloro-4-iodo-5-phenylisothiazole **7** (30 mg, 0.093 mmol), phenylzinc chloride (0.558 μ l, 0.5 M in THF, 3 equiv.) and (PPh₃)₂PdCl₂ (3.3 mg, 5 mol%) in dry and degassed DMF (2 ml) under an argon atmosphere, was heated to *ca.* 100 °C, until no starting material remained (TLC). The mixture was allowed to cool to *ca.* 20 °C, diluted with DCM (15 ml) and washed with H₂O (4 \times 10 ml). The organic layer was separated, dried and absorbed on silica. Chromatography (hexane–DCM, 6 : 4) gave 3-chloro-5-phenylisothiazole **11** (14.6 mg, 80%) as colourless needles, mp 50–51 °C (lit.,³⁴ 56 °C) (from pentane); ν_{max} /cm⁻¹ 3092w (isothiazole CH), 3065w, 3052w and 3028w (Ph CH), 1616w, 1524m, 1483s, 1447m, 1395m, 1333m, 1312m, 1220w, 1137m, 1103w, 1074w, 1031w, 1001w, 980m, 916w, 876m, 834m, 814m, 754s, 719m; δ_{H} (300 MHz; CDCl₃) 7.58–7.53 (2H, m, Ph H), 7.50–7.43 (3H, m, Ph H), 7.23 (1H, s, isothiazole *H*-4); δ_{C} (75 MHz; CDCl₃) 169.4, 150.0, 130.3 (Ph CH), 129.8 (Ph C), 129.4 (Ph CH), 126.3 (Ph CH), 119.0 (isothiazole *H*-4); δ_{C} (75 MHz; DEPT 90, CDCl₃) 130.3 (Ph CH), 129.4 (Ph CH), 126.3 (Ph CH), 119.0 (isothiazole *C*-4); *m/z* (EI) 197 (M⁺+2, 37%), 195 (M⁺, 100), 160 (25), 149 (12), 133 (9), 128 (6), 127 (10), 116 (17), 102 (10), 93 (9), 89 (15), 77 (18), 63 (12), 51 (24). Further elution (hexane–

DCM, 6 : 4) gave the *title compound* **8** (5.0 mg, 20%) as colourless needles, mp 106–107 °C (from pentane) identical to that described above.

3-Chloro-5-phenylisothiazole 11

A stirred mixture of 3-chloro-4-iodo-5-phenylisothiazole **7** (30 mg, 0.093 mmol) and Pd(OAc)₂ (20.9 mg, 0.093 mmol, 1 equiv.) in dry and degassed DMF (2 ml) under an argon atmosphere, was heated to *ca.* 140 °C, until no starting material remained (TLC). The mixture was allowed to cool to *ca.* 20 °C, diluted with DCM (15 ml) and washed with H₂O (4 × 10 ml). The organic layer was separated, dried and absorbed on silica. Chromatography (hexane–DCM, 6 : 4) gave the *title compound* **11** (17.8 mg, 98%) as colourless needles, mp 50–51 °C (lit.,³⁴ 56 °C) (from pentane) identical to that described above.

3-Hydroxy-4,5-diphenylisothiazole 12

A mixture of 3-chloro-4,5-diphenylisothiazole **8** (1 g, 3.68 mmol) and KOH (825 mg, 14.7 mmol, 4 equiv.) in H₂O (150 ml) was placed in a bomb reactor with a teflon liner. The bomb reactor was sealed and heated to *ca.* 200 °C (250 psi) for 24 h. The bomb reactor was cooled to *ca.* 20 °C and opened. The reaction mixture was filtered and the filtrate was acidified to give a white precipitate. The white precipitate was filtered, washed (H₂O) and dried to give the title compound **12** (885 mg, 95%) as colourless needles, mp 233–235 °C (lit.,³⁵ 245–247 °C) (from cyclohexane); (Found: C, 71.0; H, 4.4; N, 5.6. C₁₅H₁₁NOS requires C, 71.1; H, 4.4; N, 5.5%); λ_{max} (DCM)/nm 234 (log ε 3.94), 280 (3.90); ν_{max} /cm⁻¹ 3059w (Ar CH), 1607w, 1583w, 1566w, 1500m, 1481m, 1444w, 1342w, 1265m, 1184w, 1081w, 1073w, 1057w, 1033w, 1024w, 943w, 880m, 851w, 844w, 770m, 754s; δ_H(300 MHz; DMSO-d₆) 11.97 (1H,

br s, OH), 7.34-7.29 (6H, m, Ph CH), 7.27-7.21 (4H, m, Ph CH); δ_{C} (75 MHz; DMSO-d₆) 166.8, 160.5, 132.3 (Ph C), 131.1 (Ph C), 129.8 (Ph CH), 129.2 (Ph CH), 129.0 (Ph CH), 128.3 (Ph CH), 127.9 (Ph CH), 127.4 (Ph CH), 122.1; δ_{C} (75 MHz; DEPT 90, CDCl₃) 129.8 (Ph CH), 129.2 (Ph CH), 129.0 (Ph CH), 128.3 (Ph CH), 127.9 (Ph CH), 127.4 (Ph CH); *m/z* (EI) 254 (M⁺+1, 20%), 253 (M⁺, 100), 252 (54), 238 (6), 219 (7), 209 (17), 205 (10), 190 (6), 178 (29), 165 (32), 152 (10), 139 (4), 126 (6), 121 (4), 104 (12), 89 (8), 77 (11), 63 (6), 51 (10) (Found: M⁺, 253.0567, C₁₅H₁₁NOS requires *M*, 253.0561).

3-Bromo-4,5-diphenylisothiazole 13

A stirred mixture of 3-hydroxy-4,5-diphenylisothiazole **12** (30 mg, 0.12 mmol) and POBr₃ (1.5 g), protected with CaCl₂ drying tube, was heated to *ca.* 100 °C for 24 h. The reaction mixture was cooled to *ca.* 20 °C, diluted with water and extracted with DCM (4 × 10 ml). The organic extracts were combined, dried and absorbed on silica. Chromatography (hexane–DCM, 7 : 3) gave the *title compound* **13** (32 mg, 85%) as colourless crystals, mp 112-113 °C (from pentane); (Found: C, 56.9; H, 3.3; N, 4.3. C₁₅H₁₀BrNS requires C, 57.0; H, 3.2; N, 4.4%); λ_{max} (DCM)/nm 276 (log ε 3.01); ν_{max} /cm⁻¹ 1533w, 1498w, 1474w, 1444w, 1372w, 1339m, 1227m, 1182w, 1138w, 1075w, 1034w, 988w, 920w, 898w, 849w, 843w, 825m, 785w, 769m, 747s; δ_{H} (300 MHz; CDCl₃) 7.43-7.40 (3H, m, Ph CH), 7.35-7.26 (5H, m, Ph CH), 7.22-7.17 (2H, m, Ph CH); δ_{C} (75 MHz; CDCl₃) 164.0, 140.0, 135.3, 132.5, 130.4 (Ph CH), 130.0, 129.5 (Ph CH), 128.9 (Ph CH), 128.6 (Ph CH), 128.3 (Ph CH), 128.3 (Ph CH); δ_{C} (75 MHz; DEPT 90, CDCl₃) 130.4 (Ph CH), 129.5 (Ph CH), 128.9 (Ph CH), 128.6 (Ph CH), 128.3 (Ph CH), 128.3 (Ph CH); *m/z* (EI) 317 (M⁺+2, 97%), 315 (M⁺, 100), 302 (7), 300 (7), 236 (71), 235 (61), 221 (4), 208 (15), 203 (65), 190 (21), 178 (16), 165 (24), 152 (9), 139 (6), 121 (12), 118 (16), 104 (22), 89 (11), 77 (77), 63 (12), 51 (49).

3-Chloro-4,5-diphenylisothiazole 8 from 3-hydroxy-4,5-diphenylisothiazole 12

A stirred mixture of 3-hydroxy-4,5-diphenylisothiazole **12** (20 mg, 0.079 mmol) and POCl₃ (1 ml) was placed in a sealed tube and heated to *ca.* 150 °C for 72 h. The reaction mixture was cooled to *ca.* 20 °C, diluted (H₂O) and extracted with DCM (4 × 10 ml). The organic extracts were combined, dried and absorbed on silica. Chromatography (hexane–DCM, 7 : 3) gave the *title compound* **8** (21 mg, 98%) as colourless needles, mp 106-107 °C (from pentane) identical to that described above.

4,5-Diphenylisothiazol-3-yl trifluoromethanesulfonate 14

To a stirred solution of 3-hydroxy-4,5-diphenylisothiazole **12** (30 mg, 0.118 mmol) and triethylamine (16.5 μ l, 0.118 mmol, 1 equiv.) in DCM (2 ml) cooled to *ca.* 0 °C and protected with CaCl₂ drying tube was added dropwise trifluoromethanesulfonic anhydride (20 μ l, 0.118 mmol, 1 equiv.). The reaction mixture was kept at *ca.* 0 °C until no starting material remained (TLC). Chromatography (hexane–DCM, 7 : 3) gave the *title compound* **14** (32.3 mg, 71%) as colourless crystals mp 66-67 °C (from pentane) (Found: C, 50.1; H, 2.7; N, 3.7. C₁₆H₁₀F₃NO₃S₂ requires C, 49.9; H, 2.6; N, 3.6%); λ_{max} (DCM)/nm 277 (log ε 2.94); ν_{max} /cm⁻¹ 1449w, 1424m, 1409w, 1374m, 1274w, 1233s, 1220s, 1162w, 1132m, 1080w, 1042m, 1018w, 1000w, 941m, 922w, 877m, 856m, 802s, 773w, 763m, 751m, 736m; δ_{H} (300 MHz; CDCl₃) 7.42-7.31 (6H, m, Ph CH), 7.27-7.24 (4H, m, Ph CH); δ_{C} (75 MHz; CDCl₃) 166.2, 154.4, 130.1 (Ph CH), 129.8 (Ph CH), 129.8 (Ph C), 129.4 (Ph C), 129.1 (Ph CH), 128.9 (Ph CH), 128.8 (Ph CH), 128.2 (Ph CH), 125.4, 118.3 (1C, q, $^1J_{\text{CF}}$ 321.0, CF₃); δ_{C} (75 MHz; DEPT 90, CDCl₃) 130.1 (Ph CH), 129.8 (Ph CH), 129.1 (Ph CH), 128.9 (Ph CH), 128.8 (Ph CH), 128.2 (Ph CH); m/z (EI) 386 (M⁺+1, 16%), 385 (M⁺, 77), 252 (100), 234 (10), 219 (19), 210 (11), 190 (16), 178 (43), 176 (20), 152 (14), 139 (4), 126 (6),

121 (6), 89 (4) 77 (10), 69 (19). Further elution (hexane–Et₂O, 2 : 8) gave *4,5-diphenyl-2-(trifluoromethylsulfonyl)isothiazol-3(2H)-one* **15** (13.2 mg, 29%) as colourless crystals mp 96–97 °C (from pentane) (Found: C, 50.1; H, 2.7; N, 3.5. C₁₆H₁₀F₃NO₃S₂ requires C, 49.9; H, 2.6; N, 3.6%); $\lambda_{\text{max}}(\text{DCM})/\text{nm}$ 236 (log ε 3.05), 307 (2.83); $\nu_{\text{max}}/\text{cm}^{-1}$ 1715s (C=O), 1653w, 1599w, 1579w, 1564w, 1560w, 1506w, 1487w, 1451w, 1445w, 1415s, 1397w, 1337w, 1235s, 1200s, 1170w, 1138s, 1131s, 1081w, 1030w, 1001s, 976w, 971w, 933w, 925w, 855w, 840w, 796m, 768m, 754s, 729m; δ_{H} (300 MHz; CDCl₃) 7.52–7.47 (1H, m, Ph CH), 7.43–7.29 (9H, m, Ph CH); δ_{C} (75 MHz; CDCl₃) 163.9, 157.3, 131.8 (Ph CH), 129.8 (Ph C), 129.7 (Ph CH), 129.6 (Ph CH), 128.9 (Ph CH), 128.6 (Ph CH), 128.0 (Ph CH), 121.0, 119.2 (1C, q, ¹J_{CF} 324.3, CF₃); δ_{C} (75 MHz; DEPT 90, CDCl₃) 131.8 (Ph CH), 129.7 (Ph CH), 129.6 (Ph CH), 128.9 (Ph CH), 128.6 (Ph CH), 128.0 (Ph CH); m/z (EI) 386 (M⁺+1, 12%), 385 (M⁺, 59), 252 (100), 234 (9), 219 (20), 210 (12), 190 (12), 178 (45), 176 (21), 165 (20), 152 (14), 139 (4), 126 (5), 121 (7), 89 (6) 77 (11), 69 (23), 63 (5), 51 (9).

3-Amino-4,5-diphenylisothiazole 16

A stirred mixture of 3-chloro-4,5-diphenylisothiazole **8** (50 mg, 0.184 mmol) and sodium amide (71.8 mg, 1.84 mmol, 10 equiv.) in dry THF (2 ml) was kept to *ca.* 20 °C, under argon, until no starting material remained (TLC). Chromatography (hexane–DCM, 3 : 7) gave the *title compound* **16** (45 mg, 97%) as colourless needles, mp 130–131 °C (from cyclohexane); (Found: C, 71.4; H, 4.8; N, 10.9. C₁₅H₁₂N₂S requires C, 71.4; H, 4.8; N, 11.1%); $\lambda_{\text{max}}(\text{DCM})/\text{nm}$ 276 (log ε 3.71); $\nu_{\text{max}}/\text{cm}^{-1}$ 3458w and 3302w (NH), 3196 (Ar CH), 1622m, 1576w, 1558w, 1541w, 1506w, 1495m, 1458m, 1443w, 1402m, 1339w, 1161w, 1072w, 1053w, 1028w, 999w, 934w, 924w, 851w, 843m, 772m, 756s, 739w, 704s; δ_{H} (300 MHz; CDCl₃) 7.42–7.23 (10H, m, Ph

CH), 4.37 (2H, br s, *NH*₂); δ_{C} (75 MHz; CDCl₃) 162.9, 161.5, 133.0 (Ph *C*), 131.0 (Ph *C*), 129.9 (Ph CH), 129.2 (Ph CH), 128.9 (Ph CH), 128.7 (Ph CH), 128.2 (Ph CH), 128.1 (Ph CH), 122.7; δ_{C} (75 MHz; DEPT 90, CDCl₃) 129.9 (Ph CH), 129.2 (Ph CH), 128.9 (Ph CH), 128.7 (Ph CH), 128.2 (Ph CH), 128.1 (Ph CH); *m/z* (EI) 253 (M⁺+1, 27%), 252 (M⁺, 100), 251 (59), 234 (5), 218 (12), 209 (7), 190 (13), 178 (10), 176 (10), 165 (28), 152 (7), 139 (4), 126 (6), 121 (4), 104 (8), 89 (8), 77 (12), 74 (9), 69 (3), 63 (5), 51 (10) (Found: M⁺, 252.0718, C₁₅H₁₂N₂S requires *M*, 252.0721).

Sandmeyer iodination reaction of 3-amino-4,5-diphenylisothiazole **16**

To a stirred mixture of benzyltriethylammonium iodide (113.9 mg, 0.357 mmol, 3 equiv.) and isoamyl nitrite (63.9 μ l, 0.476 mmol, 4 equiv.) in MeCN (2 ml) protected with CaCl₂ drying tube at *ca.* 20 °C was added dropwise an MeCN (1 ml) solution of 3-amino-4,5-diphenyl-isothiazole **16** (30 mg, 0.119 mmol). The mixture was kept at *ca.* 20 °C for 30min and then was heated to *ca.* 80 °C for 1h. The mixture was allowed to cool to *ca.* 20 °C and absorbed on silica. Chromatography (hexane-DCM, 7 : 3) gave a colourless material which was a mixture of inseparable compounds: $\nu_{\text{max}}/\text{cm}^{-1}$ 2954w, 2923m, 2854w, 2208w (C≡N), 1594w, 1582w, 1576w, 1564w, 1485w, 1467w, 1457w, 1444m, 1378w, 1363w, 1331w, 1262w, 1222w, 1180w, 1157w, 1134w, 1078w, 1046w, 1031w, 998w, 985w, 969w, 919w, 900w, 873w, 854w, 822w, 793w, 768s, 746m, 738s; δ_{H} (300 MHz; CDCl₃) 7.63-7.60 (m, Ph CH), 7.54-7.40 (m, Ph CH), 7.26-7.12 (m, PhCH); δ_{C} (75 MHz; CDCl₃) 142.0, 141.1, 137.9, 133.8, 130.7 (Ph CH), 130.4 (Ph CH), 129.6 (Ph CH), 129.6, 129.1 (Ph CH), 129.1 (Ph CH), 128.9 (Ph CH), 128.8 (Ph CH), 128.7 (Ph CH), 128.6 (Ph CH), 128.5 (Ph CH), 128.4 (Ph CH), 128.3 (Ph CH), 125.1, 121.1, 121.0, 116.8, 115.8; δ_{C} (75 MHz; DEPT 90, CDCl₃) 130.7 (Ph CH), 130.4 (Ph CH), 129.6 (Ph CH), 129.1 (Ph CH), 129.1 (Ph

CH), 128.9 (Ph CH), 128.8 (Ph CH), 128.7 (Ph CH), 128.6 (Ph CH), 128.5 (Ph CH), 128.4 (Ph CH), 128.3 (Ph CH); *m/z* (EI) 364 ($M^++1\%$), 363 (M^+ , 19), 332 (6), 331 ($C_{15}H_{10}IN^+$, 33), 236 (8), 205 (17), 204 (100), 203 (37), 202 (7), 177 (22), 176 (17), 127 (8), 102 (10), 88 (13), 77 (33), 51 (29).

3,4,5-Triphenylisothiazole 17

A stirred mixture of 3-bromo-4,5-diphenylisothiazole **13** (30 mg, 0.095 mmol), phenylzinc chloride (570 μ l, 0.5 M in THF, 3 equiv.) and $(PPh_3)_2PdCl_2$ (3.3 mg, 5 mol%) in dry and degassed DMF (2 ml) under an argon atmosphere, was heated to *ca.* 100 °C, until no starting material remained (TLC). The mixture was allowed to cool to *ca.* 20 °C, diluted with DCM (15 ml) and washed with H₂O (4 \times 10 ml). The organic layer was separated, dried and absorbed on silica. Chromatography (hexane–DCM, 5 : 5) gave the title compound **17** (21.4 mg, 72%) as colourless crystals, mp 210-211 °C (lit.,¹⁷ 211.5-212.5 °C) (from cyclohexane); (Found: C, 80.5; H, 4.8; N, 4.4. $C_{21}H_{15}NS$ requires C, 80.5; H, 4.8; N, 4.5%); λ_{max} (DCM)/nm 241 (log ϵ 4.06), 284 (3.85); ν_{max}/cm^{-1} 3063w (Ph CH), 1601w, 1576w, 1539w, 1533w, 1499w, 1479w, 1440w, 1398w, 1363w, 1291w, 1272w, 1188w, 1179w, 1159w, 1153w, 1073w, 1030w, 977w, 920w, 908w, 842w, 802w, 782w, 764m, 748s, 726m, 701m; δ_H (300 MHz; CDCl₃) 7.44-7.41 (2H, m, Ph CH), 7.37-7.23 (11H, m, Ph CH), 7.13-7.10 (2H, m, Ph CH); δ_C (75 MHz; CDCl₃) 167.6, 164.0, 135.7, 134.2, 134.1, 131.0, 130.6 (Ph CH), 128.9 (Ph CH), 128.7 (Ph CH), 128.7 (Ph CH), 128.7 (Ph CH), 128.5 (Ph CH), 128.4 (Ph CH), 128.0 (Ph CH), 127.5 (Ph CH); δ_C (75 MHz; DEPT 90, CDCl₃) 130.6 (Ph CH), 128.9 (Ph CH), 128.7 (Ph CH), 128.7 (Ph CH), 128.7 (Ph CH), 128.5 (Ph CH), 128.4 (Ph CH), 128.0 (Ph CH), 127.5 (Ph CH); *m/z* (EI) 314 (M^++1 , 30%), 313 (M^+ ,

98), 312 (100), 297 (3), 280 (3), 278 (3), 236 (4), 210 (5), 208 (5), 178 (10), 165 (24), 155 (7), 149 (10), 139 (4), 126 (3), 121 (4), 103 (4), 89 (5), 77 (14), 63 (4), 51 (9).

3-Iodo-5-phenylisothiazole-4-carboxamide 19

A stirred solution of 3-iodo-5-phenylisothiazole-4-carbonitrile **18** (2 g, 6.41 mmol) in c. H₂SO₄ (50 ml) protected with CaCl₂ drying tube, was heated to *ca.* 100 °C until no starting material remained (TLC). The mixture was allowed to cool to *ca.* 20 °C and then was poured into ice-water to form a white precipitate. The white precipitate was filtered out, washed (H₂O) and dried under vacuum to give the *title compound 19* (2.12 g, 100%) as colourless crystals, mp 184-185 °C (from PhH); (Found: C, 36.4; H, 2.1; N, 8.5. C₁₀H₇IN₂OS requires C, 36.4; H, 2.1; N, 8.5%); λ_{max} (DCM)/nm 274 (log ε 3.90); ν_{max} /cm⁻¹ 3375w (NH), 3186w (Ph CH), 1643s (C=O), 1617w, 1522w, 1485w, 1415m, 1363w, 1289w, 1259m, 1228w, 1119w, 1080w, 1036w, 993w, 940w, 917w, 830w, 787w, 772m, 756w; δ_{H} (300 MHz; CD₂Cl₂) 7.58-7.55 (2H, m, Ph CH), 7.51-7.45 (3H, m, Ph CH), 5.91 (1H, br s, NH), 5.69 (1H, br s, NH); δ_{C} (75 MHz; CD₂Cl₂) 166.7, 165.1, 130.9 (Ph CH), 129.7 (Ph CH), 128.7, 128.6, 128.4 (Ph CH), 111.0; δ_{C} (75 MHz; DEPT 90, CD₂Cl₂) 130.9 (Ph CH), 129.7 (Ph CH), 128.4 (Ph CH); *m/z* (EI) 331 (M⁺+1, 15%), 330 (M⁺, 100), 329 (80), 314 (46), 202 (10), 187 (10), 159 (24), 133 (16), 127 (18), 121 (13), 116 (11), 100 (6), 89 (27), 77 (29), 63 (9), 51 (22).

3-Iodo-5-phenylisothiazole-4-carboxylic acid 20

To a stirred solution of 3-iodo-5-phenylisothiazole-4-carboxamide **19** (49.5 mg, 0.15 mmol) in c. H₂SO₄ (1 ml) cooled to *ca.* 0 °C and protected with CaCl₂ drying tube, was added in portions sodium nitrite (259 mg, 3.75 mmol, 25 equiv.). The reaction mixture was heated to *ca.* 100 °C, until no starting material remained (TLC). The

mixture was allowed to cool to *ca.* 20 °C and then was poured into ice-water to form a white precipitate. The white precipitate was filtered out, washed (H₂O) and dried under vacuum to give the *title compound* **20** (38.7 mg, 78%) as colourless needles, mp 156-157 °C (from cyclohexane); (Found: C, 36.3; H, 1.8; N, 4.3. C₁₀H₆INO₂S requires C, 36.3; H, 1.8; N, 4.2%); $\lambda_{\text{max}}(\text{DCM})/\text{nm}$ 230 (log ε 2.78), 273 (2.86); $\nu_{\text{max}}/\text{cm}^{-1}$ 1689s (C=O), 1537w, 1507m, 1473s, 1445w, 1433m, 1371m, 1337m, 1282w, 1267w, 1220m, 1076w, 1034w, 1006w, 962w, 915w, 828s, 788w, 773w, 754w, 735s; δ_{H} (300 MHz; CD₂Cl₂) 8.83 (1H, br s, OH), 7.55-7.45 (5H, m, Ph CH); δ_{C} (75 MHz; CD₂Cl₂) 173.1, 166.6, 130.9 (Ph CH), 129.9, 129.1 (Ph CH), 129.0 (Ph CH), 128.9, 112.6; δ_{C} (75 MHz; DEPT 90, CD₂Cl₂) 130.9 (Ph CH), 129.1 (Ph CH), 129.0 (Ph CH); *m/z* (EI) 332 (M⁺+1, 13%), 331 (M⁺, 100), 330 (24), 314 (35), 187 (4), 186 (5), 159 (13), 133 (13), 127 (14), 121 (7), 116 (12), 100 (5), 89 (22), 77 (28), 69 (5), 63 (7), 51 (23).

4-Amino-3-iodo-5-phenylisothiazole 21

To a stirred solution of sodium hydroxide (18.2 mg, 0.455 mmol, 5 equiv.) in water (2 ml) cooled to *ca.* 0 °C was first added Br₂ (5.6 μl, 0.109 mmol 1.2 equiv.) and then 3-iodo-5-phenylisothiazole-4-carboxamide **19** (30 mg, 0.091 mmol). The reaction mixture was allowed to warm to *ca.* 20 °C and was kept at this temperature until the starting material had completely dissolved. The reaction mixture was then heated to *ca.* 70 °C for 1 h. The mixture was allowed to cool to *ca.* 20 °C, diluted with water (2 ml) and extracted with DCM (4 × 10 ml). The organic extracts were combined, dried and absorbed on silica. Chromatography (hexane-DCM, 5 : 5) gave the *title compound* **21** (24.5 mg, 89%) as orange cubes, mp 74-76 °C (from cyclohexane); (Found: C, 35.9; H, 2.3; N, 9.3. C₉H₇IN₂S requires C, 35.8; H, 2.3; N, 9.3%); $\lambda_{\text{max}}(\text{DCM})/\text{nm}$ 231 (log ε 2.76), 266 (2.68), 320 (2.86); $\nu_{\text{max}}/\text{cm}^{-1}$ 3368w and 3308

(NH), 1622w, 1597w, 1572w, 1538w, 1487w, 1442w, 1400m, 1347m, 1316w, 1275w, 1182w, 1157w, 1117w, 1078w, 1040m, 999w, 992w, 970w, 926w, 859w, 807m, 773m, 761s; δ_{H} (300 MHz; CD₂Cl₂) 7.52-7.37 (5H, m, Ph CH), 3.96 (2H, br s, NH); δ_{C} (75 MHz; CD₂Cl₂) 140.4, 138.1, 130.6 (Ph C), 129.8 (Ph CH), 129.1 (Ph CH), 127.7 (Ph CH), 108.5; δ_{C} (75 MHz; DEPT 90, CD₂Cl₂) 129.8 (Ph CH), 129.1 (Ph CH), 127.7 (Ph CH); *m/z* (EI) 303 (M⁺+1, 11%), 302 (M⁺, 100), 175 (15), 148 (31), 142 (78), 127 (4), 121 (83), 89 (6), 77 (39), 69 (6), 63 (6), 51 (16).

3,4-Diido-5-phenylisothiazole 22

To a stirred mixture of I₂ (62.9 mg, 0.248 mmol, 2.5 equiv.) and isoamyl nitrite (53.2 μ l, 0.396 mmol, 4 equiv.) in MeCN (2 ml) protected with CaCl₂ drying tube at *ca.* 80 °C was added dropwise an MeCN (1 ml) solution of 4-amino-3-iodo-5-phenylisothiazole **21** (30 mg, 0.099 mmol). The mixture was kept at *ca.* 80 °C until no starting material remained (TLC), allowed to cool to *ca.* 20 °C and absorbed on silica. Chromatography (hexane-DCM, 7 : 3) gave the *title compound 22* (34.8 mg, 85%) as colourless plates, mp 84-85 °C (from pentane); (Found: C, 26.2; H, 1.2; N, 3.4. C₉H₅I₂NS requires C, 26.2; H, 1.2; N, 3.4%); λ_{max} (DCM)/nm 281 (log ε 3.72); ν_{max} /cm⁻¹ 3046w (Ph CH), 1459s, 1439m, 1356m, 1317w, 1290w, 1235s, 1217m, 1202w, 1076w, 1033m, 971m, 920w, 870s, 841w, 800m, 766s, 745s; δ_{H} (300 MHz; CDCl₃) 7.56-7.44 (5H, m, Ph CH); δ_{C} (75 MHz; CDCl₃) 166.9, 130.6, 130.3 (Ph CH), 128.9 128.9 (Ph CH), 128.7 (Ph CH), 125.5; δ_{C} (75 MHz; DEPT 90, CDCl₃) 130.3 (Ph CH), 128.9 (Ph CH), 128.7 (Ph CH); *m/z* (EI) 414 (M⁺+1, 12%), 413 (M⁺, 100), 286 (M⁺-I, 2), 254 (2), 206 (3), 159 (M⁺-2I, 89), 133 (5), 127 (26), 115 (11), 100 (7), 89 (8), 77 (12), 69 (5), 63 (8), 51 (17).

4-Bromo-3-iodo-5-phenylisothiazole 24

To a stirred mixture of 3-iodo-5-phenylisothiazole-4-carboxylic acid **20** (1.0 g, 3.02 mmol) in H₂O (50 ml) was added aqueous solution of KOH (169.5 mg, 3.02 mmol, 1 equiv.) and the mixture was allowed to stirred at *ca.* 20 °C until the complete solution of the starting material. To the reaction mixture was added, in one portion, a solution of silver nitrate (513 mg, 3.02 mmol, 1 equiv.) in H₂O (5 ml) to form a white-grey precipitate. The white-grey precipitate was filtered out, washed first with H₂O and then with acetone and dried in a vacuum oven at *ca.* 80 °C for 12 h to give the *title compound* **23** (1.32 g, 100%). To a stirred mixture of silver 3-iodo-5-phenylisothiazole-4-carboxylate **23** (50 mg, 0.114 mmol) in tetrachloromethane (3 ml) protected with CaCl₂ drying tube was added in one portion Br₂ (7.02 µl, 0.137 mmol, 1.2 equiv.) and the reaction was kept at 20 °C for 1 h. The reaction mixture was filtered and the filtrate was absorbed on silica. Chromatography (hexane-DCM 8 : 2) gave the *title compound* **24** (31.3mg, 75%) as pale yellow oil; (Found: C, 29.5; H, 1.8; N, 3.8. C₉H₅BrINS requires C, 29.5; H, 1.4; N, 3.8%); $\lambda_{\text{max}}(\text{DCM})/\text{nm}$ 280 (log ε 2.82); $\nu_{\text{max}}/\text{cm}^{-1}$ 3062w (Ph CH), 2921w, 1575w, 1521w, 1467s, 1442m, 1361w, 1250s, 1224w, 1210w, 1075w, 1032w, 977w, 917w, 884s, 802m, 767m, 744s; δ_{H} (300 MHz; CDCl₃) 7.62-7.56 (2H, m, Ph CH), 7.54-7.47 (3H, m, Ph CH); δ_{C} (75 MHz; CDCl₃) 161.9, 130.3 (Ph CH), 129.1 (Ph CH), 129.0 (Ph C), 128.4 (Ph CH), 119.7, 115.4; δ_{C} (75 MHz; DEPT 90, CDCl₃) 130.3 (Ph CH), 129.0 (Ph CH), 128.4 (Ph CH); *m/z* (EI) 367 (M⁺+2, 83%), 365 (M⁺, 81), 240 (3), 238 (M⁺-I, 3), 159 (100), 127 (34), 121 (7), 115 (13), 114 (11), 100 (9), 89 (10), 77 (24), 69 (10), 63 (13), 51 (35).

Suzuki reaction on 4-bromo-3-iodo-5-phenylisothiazole 24

A stirred mixture of 4-bromo-3-iodo-5-diphenylisothiazole **24** (30 mg, 0.082 mmol), phenylboronic acid (30.0 mg, 0.246 mmol, 3 equiv.), powdered K₂CO₃ (17.0 mg, 0.123 mmol, 1.5 equiv.) and Pd(OAc)₂ (0.9 mg, 5 mol%) in dry and degassed DMF (2 ml) under an argon atmosphere, was heated to *ca.* 140 °C, until no starting material remained (TLC). The mixture was allowed to cool to *ca.* 20 °C, diluted with DCM (15 ml) and washed with H₂O (4 × 10 ml). The organic layer was separated, dried and absorbed on silica. Chromatography (hexane–DCM, 7 : 3) gave a colourless material which was (tentatively) an inseparable mixture of mainly 4-bromo-3,5-diphenylisothiazole **30** (see below for independent synthesis and characterisation) and a trace of 3-iodo-4,5-diphenylisothiazole; (Found: C, 55.8; H, 3.1; N, 4.0); δ_H(300 MHz; CDCl₃) 7.86-7.83 (2H, m, Ph CH), 7.68-7.65 (2H, m, Ph CH), 7.54-7.42 (6H, m, PhCH); *m/z* (EI) 364 (M⁺+1, 3%), 363 (M⁺, C₁₅H₁₀INS, 15), 318 (17), 317 (M⁺, C₁₅H₁₀Br⁸¹NS, 100), 316 (19), 315 (M⁺, C₁₅H₁₀Br⁷⁹NS, 93), 237 (32), 236 (77), 235 (27), 204 (10), 203 (17), 189 (11), 135 (11), 134 (26), 133 (31), 118 (25), 104 (11), 89 (52), 77 (31), 63 (11), 57 (8), 51 (21).

3,3'-Bi(4-bromo-5-phenylisothiazole) **25**

A stirred mixture of 4-bromo-3-iodo-5-phenylisothiazole **24** (30 mg, 0.082 mmol) and Pd(OAc)₂ (18.4 mg, 0.082 mmol, 1 equiv.) in DMF (2 ml) under an argon atmosphere, was heated to *ca.* 140 °C, until no starting material remained (TLC). The mixture was allowed to cool to *ca.* 20 °C, diluted with DCM (15 ml) and washed with H₂O (4 × 10 ml). The organic layer was separated, dried and absorbed on silica. Chromatography (hexane–DCM, 2 : 8) gave the *title compound* **25** (14.5 mg, 74%) as colourless needles, mp 208-209 °C (from cyclohexane); (Found: C, 45.4; H, 2.2; N, 6.0. C₁₈H₁₀Br₂N₂S₂ requires C, 45.2; H, 2.1; N, 5.9%); λ_{max}(DCM)/nm 285 (log ε

4.09); $\nu_{\text{max}}/\text{cm}^{-1}$ 3062w (Ph CH), 1684w, 1653w, 1576w, 1559w, 1539w, 1506w, 1473m, 1445m, 1357w, 1288w, 1243s, 1213w, 1181w, 1159w, 1077w, 1056w, 1035w, 1000w, 977w, 967w, 912w, 882s, 846w, 829m, 754m, 746s, 728w, 724w; δ_{H} (300 MHz; CDCl_3) 7.74-7.66 (4H, m, Ph CH), 7.59-7.48 (6H, m, Ph CH); δ_{C} (75 MHz; CDCl_3) 163.0, 161.3, 130.1 (Ph CH), 129.4 (Ph C), 129.1 (Ph CH), 128.7 (Ph CH), 107.3; δ_{C} (75 MHz; DEPT 90, CDCl_3) 130.1 (Ph CH), 129.1 (Ph CH), 128.7 (Ph CH); m/z (EI) 480 (M^++2 , 54%), 478 (M^++2 , 100), 476 (M^+ , 50), 399 (3), 397 (3), 318 (15), 239 (8), 214 (4), 159 (18), 145 (8), 133 (42), 127 (10), 121 (13), 101 (4), 89 (40), 77 (10), 63 (6), 51 (8).

3,5-Diphenylisothiazole-4-carboxamide 27

A stirred solution of 3,5-diphenylisothiazole-4-carbonitrile **26** (1 g, 3.81 mmol) in c. H_2SO_4 (10 ml) protected with CaCl_2 drying tube, was heated to *ca.* 100 °C until no starting material remained (TLC). The mixture was allowed to cool to *ca.* 20 °C and then was poured into ice-water to afford a white precipitate. The white precipitate was filtered, washed (H_2O) and dried under vacuum to give the *title compound* **27** (1.07 g, 100%) as colourless needles, mp 210-211 °C (from PhH); (Found: C, 68.6; H, 4.4; N, 9.9. $\text{C}_{16}\text{H}_{12}\text{N}_2\text{OS}$ requires C, 68.6; H, 4.3; N, 10.0%); $\lambda_{\text{max}}(\text{DCM})/\text{nm}$ 249 (log ε 4.19), 271 (4.11); $\nu_{\text{max}}/\text{cm}^{-1}$ 3398w (NH), 3198w, 1641s (C=O), 1616w, 1560w, 1533w, 1488w, 1446w, 1430w, 1385w, 1348w, 1099w, 1079w, 1029w, 1005w, 992w, 923w, 857w, 790w, 777w, 763w; δ_{H} (300 MHz; CD_2Cl_2) 7.83-7.77 (2H, m, Ph CH), 7.65-7.59 (2H, m, Ph CH), 7.53-7.43 (6H, m, Ph CH), 5.89 (1H, br s, NH), 5.68 (1H, br s, NH); δ_{C} (75 MHz; CD_2Cl_2) 167.4, 167.3, 166.5, 135.1, 130.4 (Ph CH), 130.1, 130.1, 129.7 (Ph CH), 129.5 (Ph CH), 128.9 (Ph CH), 128.5 (Ph CH), 128.4 (Ph CH); δ_{C} (75 MHz; DEPT 90, CD_2Cl_2) 130.4 (Ph CH), 129.7(Ph CH), 129.5 (Ph CH), 128.9 (Ph CH), 128.5 (Ph CH), 128.4 (Ph CH); m/z (EI) 280 (M^+ , 91%), 279 (M^+-H , 100), 264

(50), 236 (4), 203 (5), 189 (4), 163 (3), 140 (10), 133 (29), 129 (19), 121 (9), 103 (8), 89 (37), 77 (38), 69 (6), 63 (10), 51 (23).

3,5-Diphenylisothiazole-4-carboxylic acid 28

To a stirred solution of 3,5-diphenylisothiazole-4-carboxamide **27** (1 g, 3.57 mmol) in c. H₂SO₄ (10 ml) cooled to *ca.* 0 °C and protected with CaCl₂ drying tube, was added in portions sodium nitrite (2.46 g, 35.7 mmol, 10 equiv.). The reaction mixture was heated to *ca.* 100 °C, until no starting material remained (TLC). The mixture was allowed to cool to *ca.* 20 °C and then was poured into ice-water to afford a white precipitate. The white precipitate was filtered, washed (H₂O) and dried under vacuum to give the title compound **28** (0.87 g, 87%) as colourless needles, mp 202-203 °C (lit.,³⁶ 204-206 °C) (from cyclohexane); (Found: C, 68.5; H, 3.9; N, 5.0. C₁₆H₁₁NO₂S requires C, 68.3; H, 3.9; N, 5.0%); λ_{max} (DCM)/nm 251 (log ε 4.00); v_{max} /cm⁻¹ 3055w (Ph CH), 1679s (C=O), 1559w, 1539w, 1533w, 1510m, 1476s, 1442m, 1356m, 1296m, 1208w, 1151w, 1077w, 1025w, 1005w, 990w, 953w, 917w, 856m, 821w, 801w, 769w, 755s; δ_H(300 MHz; CD₂Cl₂) 7.65-7.62 (2H, m, Ph CH), 7.56-7.53 (2H, m, Ph CH), 7.52-7.39 (6H, m, Ph CH) OH peak missing; δ_C(75 MHz; CD₂Cl₂) 171.8, 168.4, 167.5, 135.6, 130.4 (Ph CH), 130.0, 129.7 (Ph CH), 129.2 (Ph CH), 129.0 (Ph CH), 128.7 (Ph CH), 128.7 (Ph CH), 125.8; δ_C(75 MHz; DEPT 90, CD₂Cl₂) 130.4 (Ph CH), 129.7 (Ph CH), 129.2 (Ph CH), 129.0 (Ph CH), 128.7 (Ph CH), 128.7 (Ph CH); *m/z* (EI) 282 (M⁺+1, 24%), 281 (M⁺, 100), 280 (57), 264 (21), 252 (5), 248 (7), 237 (57), 220 (3), 204 (7), 190 (4), 178 (3), 176 (3), 165 (7), 141 (7), 134 (19), 133 (20), 129 (14), 121 (16), 103 (15), 89 (32), 77 (44), 69 (8), 63 (13), 51 (28).

4-Bromo-3,5-diphenylisothiazole 30

To a stirred mixture of 3,5-diphenylisothiazole-4-carboxylic acid **28** (0.5 g, 1.78 mmol) in H₂O (50 ml) was added an aqueous solution of KOH (99.9 mg, 1.78 mmol, 1 equiv.) in H₂O (10 ml) and the mixture was allowed to stirred at *ca.* 20 °C until the starting material had completely dissolved. To the reaction mixture was added, in one portion, a solution of silver nitrate (302 mg, 1.78 mmol, 1 equiv.) in water (5 ml) to afford a white-grey precipitate. The white-grey precipitate was filtered, washed first with water and then with acetone and dried in a vacuum oven at *ca.* 80 °C for 12 h to give the *title compound* **29** (0.69 g, 100%). To a stirred mixture of silver 3,5-diphenylisothiazole-4-carboxylate **29** (100 mg, 0.258 mmol) in tetrachloromethane (3 ml) protected with CaCl₂ drying tube was added in one portion Br₂ (15.9 μ l, 0.31 mmol, 1.2 equiv.) and the reaction was kept at 20 °C for 1 h. The reaction mixture was filtered and the filtrate was absorbed on silica. Chromatography (hexane-DCM 8 : 2) gave the *title compound* **30** (65.3 mg, 80%) as colourless needles, mp 114-115 °C (from pentane); (Found: C, 57.2; H, 3.2; N, 4.6. C₁₅H₁₀BrNS requires C, 57.0; H, 3.2; N, 4.4%); λ_{max} (DCM)/nm 238 (log ε 4.03), 282 (3.96); ν_{max} /cm⁻¹ 3054w (Ph CH), 1684w, 1653w, 1559w, 1539w, 1521w, 1506w, 1474s, 1444s, 1399w, 1343m, 1312w, 1208w, 1143w, 1075w, 1024m, 973w, 923w, 902s, 834m, 789w, 764s, 756s; δ_{H} (300 MHz; CDCl₃) 7.88-7.83 (2H, m, Ph CH), 7.69-7.66 (2H, m, Ph CH), 7.56-7.45 (6H, m, Ph CH); δ_{C} (75 MHz; CDCl₃) 167.0, 162.9, 134.7 (Ph C), 130.1 (Ph C), 129.8 (Ph CH), 129.3 (Ph CH), 129.0 (Ph CH), 128.9 (Ph CH), 128.8 (Ph CH), 128.2 (Ph CH), 106.0; δ_{C} (75 MHz; DEPT 90, CDCl₃) 129.8 (Ph CH), 129.3 (Ph CH), 129.0 (Ph CH), 128.9 (Ph CH), 128.8 (Ph CH), 128.2 (Ph CH); *m/z* (EI) 317 (M⁺+2, 98%), 315 (M⁺, 100), 236 (78), 203 (13), 189 (12), 134 (35), 133 (47), 118 (27), 109 (16), 89 (100), 77 (45), 63 (19), 51 (32).

3,5-Diphenylisothiazole 31

A stirred mixture of 3,5-diphenylisothiazole-4-carboxylic acid **28** (50 mg, 0.178 mmol), *p*-toluenesulfonic acid (3.4 mg, 10 mol%) and biphenyl (1 g) protected with CaCl₂ drying tube, was heated to *ca.* 250 °C until no starting material remained (TLC). The mixture was allowed to cool to *ca.* 20 °C and absorbed on silica. Chromatography (hexane-DCM 8 : 2) gave the title compound **31** (39.7 mg, 94%) as colourless needles, mp 80-81 °C (lit.³⁷ 81 °C) (from pentane); (Found: C, 75.9; H, 4.6; N, 5.8. C₁₅H₁₁NS requires C, 75.9; H, 4.7; N, 5.9%); λ_{max} (DCM)/nm 256 (log ε 4.13), 280 (4.06); ν_{max} /cm⁻¹ 3055w (Ph CH), 1530w, 1448m, 1453w, 1447w, 1391w, 1370w, 1337w, 1306w, 1206w, 1188w, 1157w, 1153w, 1087w, 1075w, 1027w, 1000w, 970w, 965w, 920w, 909w, 878m, 851w, 830m, 770w, 759m, 752s; δ_H(300 MHz; CDCl₃) 8.03-7.99 (2H, m, Ph CH), 7.76 (1H, s, isothiazole CH), 7.68-7.64 (2H, m, Ph CH), 7.53-7.39 (6H, m, Ph CH); δ_C(75 MHz; CDCl₃) 168.2, 168.2, 134.8, 130.9 (Ph CH), 129.5 (Ph CH), 129.2 (Ph CH), 128.8 (Ph CH), 126.8 (Ph CH), 126.5 (Ph CH), 117.5 (isothiazole H-4) one peak missing; δ_C(75 MHz; DEPT 90, CDCl₃) 130.9 (Ph CH), 129.5 (Ph CH), 129.2 (Ph CH), 128.8 (Ph CH), 126.8 (Ph CH), 126.5 (Ph CH), 117.5 (isothiazole H-4); *m/z* (EI) 238 (M⁺+1, 19%), 237 (M⁺, 100), 204 (6), 159 (3), 134 (23), 121 (5), 118 (3), 108 (5), 103 (9), 89 (10), 77 (21), 76 (8), 69 (4), 63 (6), 51 (15).

Methyl 3,5-diphenylisothiazole-4-carbamate 32

To a stirred solution of 3,5-diphenylisothiazole-4-carboxamide **27** (0.2 g, 0.713 mmol) in methanol (3 ml) at *ca.* 20 °C, protected with CaCl₂ drying tube, was added sodium (65.6 mg, 2.85 mmol, 4 equiv.) and then Br₂ (43.9 μl, 0.856 mmol, 1.2 equiv.). The reaction mixture was heated to *ca.* 70 °C for 1 h. The mixture was

allowed to cool to *ca.* 20 °C and absorbed on silica. Chromatography (hexane-DCM 5 : 5) gave the *title compound* **32** (0.20 g, 95%) as colourless needles, mp 163-164 °C (from cyclohexane); (Found: C, 65.9; H, 4.7; N, 9.2. C₁₇H₁₄N₂O₂S requires C, 65.8; H, 4.6; N, 9.0%); λ_{max} (DCM)/nm 243 (log ε 4.00), 276 inf (3.90); ν_{max} /cm⁻¹ 3286w (NH), 1712s (C=O), 1582w, 1555w, 1522m, 1506m, 1484w, 1451w, 1424w, 1370w, 1251s, 1190w, 1181w, 1157w, 1097m, 1076w, 1037w, 1030w, 1017w, 1000w, 915w, 852w, 840w, 777w, 761s, 746s, 722w; δ_H(300 MHz; CDCl₃) 7.72-7.69 (2H, m, Ph CH), 7.51-7.42 (8H, m, Ph CH), 6.44 (1H, br s, NH), 3.62 (3H, br s, CH₃); δ_C[75 MHz; CD₂Cl₂ with Cr(acac)₃] 165.3, 162.0, 155.6, 135.2, 130.3, 130.0, 129.9 (Ph CH), 129.5 (Ph CH), 129.5 (Ph CH), 128.9 (Ph CH), 128.2 (Ph CH), 127.9 (Ph CH), 114.8, 1 peak missing; δ_C[75 MHz; DEPT 90, CD₂Cl₂ with Cr(acac)₃] 129.9 (Ph CH), 129.5 (Ph CH), 129.5 (Ph CH), 128.9 (Ph CH), 128.2 (Ph CH), 127.9 (Ph CH) 1 peak missing; *m/z* (EI) 311 (M⁺+1, 20%), 310 (M⁺, 98), 279 (17), 278 (18), 265 (6), 251 (16), 233 (4), 218 (10), 173 (5), 162 (5), 148 (29), 130 (5), 121 (100), 120 (7), 104 (13), 89 (8), 77 (62), 59 (18), 51 (22). Further elution gave 3,5-diphenylisothiazole-4-carboxamide **27** (6 mg, 3%) as colourless needles, mp 210-211 °C (from PhH) identical to that described above.

4-Amino-3,5-diphenylisothiazole 33

A stirred solution of methyl 3,5-diphenylisothiazole-4-carbamate **32** (0.5 g, 1.61 mmol) in 48% aq. HBr (20 ml) was heated to *ca.* 100 °C until no starting material remained (TLC). The mixture was allowed to cool to *ca.* 20 °C, diluted with water (10 ml) and extracted with DCM (4 × 10 ml). The organic extracts were combined, dried and absorbed on silica. Chromatography (hexane-DCM, 5 : 5) gave the *title compound* **33** (394 mg, 97%) as colourless needles, mp 113-114 °C (from

cyclohexane); (Found: C, 71.4; H, 4.9; N, 11.0. $C_{15}H_{12}N_2S$ requires C, 71.4; H, 4.8; N, 11.1%); $\lambda_{\text{max}}(\text{DCM})/\text{nm}$ 238 (log ε 3.11), 327 (4.01); $\nu_{\text{max}}/\text{cm}^{-1}$ 3430w and 3349 (NH), 3055w (Ph CH), 1734w, 1718w, 1700w, 1684w, 1653w, 1613m, 1559w, 1506w, 1487w, 1449m, 1417s, 1387w, 1340w, 1316w, 1291w, 1278w, 1232w, 1182w, 1116w, 1103w, 1079w, 1042w, 1029m, 1018m, 997w, 974w, 919w, 836m, 774w, 762w, 719w; δ_{H} (300 MHz; CDCl_3) 7.81 (2H, m, Ph CH), 7.59-7.37 (8H, m, Ph CH), 3.61 (2H, br s, NH); δ_{C} (75 MHz; CDCl_3) 159.4, 140.7, 136.2, 135.1, 131.3, 129.4 (Ph CH), 129.0 (Ph CH), 128.9 (Ph CH), 128.3 (Ph CH), 127.7 (Ph CH), 127.7 (Ph CH); δ_{C} (75 MHz; DEPT 90, CDCl_3) 129.4 (Ph CH), 129.0 (Ph CH), 128.9 (Ph CH), 128.3 (Ph CH), 127.7 (Ph CH), 127.7 (Ph CH); m/z (EI) 253 ($M^+ + 1$, 19%), 252 (M^+ , 100), 180 (2), 149 (22), 121 (68), 104 (51), 89 (8), 77 (31), 51 (10).

4-Iodo-3,5-diphenylisothiazole 34

To a stirred mixture of I_2 (151 mg, 0.594 mmol, 3 equiv.) and isoamyl nitrite (106 μl , 0.794 mmol, 4 equiv.) in MeNO_2 (2 ml) protected with CaCl_2 drying tube at *ca.* 110 °C was added dropwise an MeNO_2 (1 ml) solution of 4-amino-3,5-diphenylisothiazole **33** (50 mg, 0.198 mmol). The mixture was kept at *ca.* 110 °C until no starting material remained (TLC), allowed to cool to *ca.* 20 °C and absorbed on silica. Chromatography (hexane-DCM, 7 : 3) gave the *title compound* **34** (57.5 mg, 80%) as colourless plates, mp 138-139 °C (from cyclohexane); (Found: C, 49.7; H, 3.0; N, 3.8. $C_{15}H_{10}INS$ requires C, 49.6; H, 2.8; N, 3.9%); $\lambda_{\text{max}}(\text{DCM})/\text{nm}$ 234 (log ε 3.13), 282 (2.96); $\nu_{\text{max}}/\text{cm}^{-1}$ 3054w (Ph CH), 1468m, 1442m, 1396w, 1339w, 1331w, 1308w, 1203w, 1180w, 1140w, 1076w, 1032w, 1024w, 973w, 922w, 893s, 836w, 784w, 762s, 752m; δ_{H} (300 MHz; CDCl_3) 7.80-7.77 (2H, m, Ph CH), 7.62-7.60 (2H, m, Ph CH), 7.52-7.48 (4H, m, Ph CH); δ_{C} (75 MHz; CDCl_3) 170.0, 167.1, 135.8,

131.6, 129.8 (Ph CH), 129.4 (Ph CH), 129.3 (Ph CH), 129.1 (Ph CH), 128.9 (Ph CH), 128.1 (Ph CH), 78.8; δ_{C} (75 MHz; DEPT 90, CDCl₃) 129.8 (Ph CH), 129.4 (Ph CH), 129.3 (Ph CH), 129.1 (Ph CH), 128.9 (Ph CH), 128.1 (Ph CH); *m/z* (EI) 364 (M⁺+1, 18%), 363 (M⁺, 100), 236 (40), 203 (8), 189 (6), 165 (3), 163 (3), 133 (15), 118 (14), 109 (9), 89 (23), 77 (10), 63 (5), 51 (8).

3,4,5-Triphenylisothiazole 17 (typical Suzuki conditions for coupling at C-4: see Table 2)

A stirred mixture of 4-bromo-3,5-diphenylisothiazole **30** (50 mg, 0.158 mmol), phenylboronic acid (57.8 mg, 0.474 mmol, 3 equiv.), powdered K₂CO₃ (32.8 mg, 0.237 mmol, 1.5 equiv.) and Pd(OAc)₂ (1.8 mg, 5 mol%) in dry and degassed DMF (2 ml) under an argon atmosphere, was heated to *ca.* 110 °C, until no starting material remained (TLC). The mixture was allowed to cool to *ca.* 20 °C, diluted with DCM (15 ml) and washed with H₂O (4 × 10 ml). The organic layer was separated, dried and absorbed on silica. Chromatography (hexane–DCM, 7 : 3) gave the title compound **17** (49.5 mg, 98%) as colourless crystals, mp 210-211 °C (from cyclohexane) identical to that described above.

3,5-Diphenyl-4-(3-nitrobenzene)isothiazole 35

Similar treatment of 4-bromo-3,5-diphenylisothiazole **30** (50 mg, 0.158 mmol) with 3-nitrobenzenboronic acid (3 equiv.), powdered K₂CO₃ and Pd(OAc)₂ gave the *title compound* **35** (56 mg, 99%) as colourless needles, mp 203-204 °C (from cyclohexane); (Found: C, 70.3; H, 3.8; N, 7.9. C₂₁H₁₄N₂O₂S requires C, 70.4; H, 3.9;

N, 7.8%); λ_{\max} (DCM)/nm 245 (log ε 3.19), 274 inf (3.09); $\nu_{\max}/\text{cm}^{-1}$ 3076w and 3067w (Ar CH), 1537m, 1518s, 1491w, 1470w, 1443w, 1398w, 1350s, 1275w, 1267w, 1179w, 1163w, 1123w, 1070w, 1028w, 988w, 972w, 939w, 918w, 908w, 864w, 843w, 818w, 800w, 781m, 760m, 743s, 731s, 710m; δ_{H} (300 MHz; CDCl_3) 8.14 (1H, ddd, J 7.7, 2.0, 2.0, Ar CH), 7.93 (1H, app t, J 1.9, Ar CH), 7.46-7.26 (10H, m, Ar CH), 7.20-7.17 (2H, m, Ar CH); δ_{C} (75 MHz; CDCl_3) 167.3, 165.6, 148.2, 136.8 (Ph CH), 136.0, 134.9, 131.7, 130.1, 129.5 (Ph CH), 129.3 (Ph CH), 129.0 (Ph CH), 128.9 (Ph CH), 128.8 (Ph CH), 128.7 (Ph CH), 128.3 (Ph CH), 125.4 (Ph CH), 122.5 (Ph CH); δ_{C} (75 MHz; DEPT 90, CDCl_3) 136.8 (Ph CH), 129.5 (Ph CH), 129.3 (Ph CH), 129.0 (Ph CH), 128.9 (Ph CH), 128.8 (Ph CH), 128.7 (Ph CH), 128.3 (Ph CH), 125.4 (Ph CH), 122.5 (Ph CH); m/z (EI) 359 (M^++1 , 25%), 358 (M^+ , 100), 357 (31), 328 (4), 311 (36), 296 (3), 278 (3), 237 (3), 208 (5), 190 (2), 176 (3), 165 (8), 155 (12), 135 (5), 121 (3), 103 (3), 89 (9), 77 (8), 73 (7), 51 (4) (Found: M^+ , 358.0779, $\text{C}_{21}\text{H}_{14}\text{N}_2\text{O}_2\text{S}$ requires M , 358.0776).

3,5-Diphenyl-4-(4-methoxybenzene)isothiazole 36

Similar treatment of 4-bromo-3,5-diphenylisothiazole **30** (50 mg, 0.158 mmol) with 4-methoxybenzeneboronic acid (3 equiv.), powdered K_2CO_3 and $\text{Pd}(\text{OAc})_2$ gave the title compound **36** (53 mg, 98%) as colourless needles, mp 174-175 °C (from cyclohexane); (Found: C, 77.0; H, 4.9; N, 4.1. $\text{C}_{22}\text{H}_{17}\text{NOS}$ requires C, 76.9; H, 5.0; N, 4.1%); λ_{\max} (DCM)/nm 241 (log ε 3.45), 282 inf (3.08); $\nu_{\max}/\text{cm}^{-1}$ 3063w (Ar CH) and 2930w, 1611w, 1574w, 1539w, 1508w, 1483w, 1470w, 1456w, 1441w, 1400w, 1364w, 1287m, 1273w, 1248s, 1173m, 1157w, 1103w, 1072w, 1030m, 982w, 966w, 907w, 851w, 822m, 777m, 760m, 733s, 719m; δ_{H} (300 MHz; CDCl_3) 7.41 (2H, app d, J 6.9, Ar CH), 7.32-7.21 (8H, m, Ar CH), 6.99 (2H, d, J 8.6, Ar CH), 7.80 (2H, d, J

8.50, Ar CH), 3.80 (3H, s, OCH₃; δ_C(75 MHz; CDCl₃) 167.7, 163.6, 158.9, 135.8, 133.8, 131.7 (Ph CH), 131.1, 128.9 (Ph CH), 128.7 (Ph CH), 128.4 (Ph CH), 128.0 (Ph CH), 126.1, 114.0 (Ph CH), 55.1, 1 peak missing; δ_C(75 MHz; DEPT 90, CDCl₃) 131.7 (Ph CH), 128.9 (Ph CH), 128.7 (Ph CH), 128.7, (Ph CH), 128.4 (Ph CH), 128.0 (Ph CH), 114.0 (Ph CH), 1 peak missing; *m/z* (EI) 344 (M⁺+1, 25%), 343 (M⁺, 100), 328 (3), 312 (3), 256 (2), 225 (7), 208 (7), 193 (3), 165 (7), 152 (3), 81 (3), 77 (3), 69 (8), 60 (3), 57 (4), 55 (5), (Found: M⁺, 343.1031, C₂₂H₁₇NOS requires *M*, 343.1031).

3,5-Diphenyl-4-(3-methoxybenzene)isothiazole 37

Similar treatment of 4-bromo-3,5-diphenylisothiazole **30** (50 mg, 0.158 mmol) with 3-methoxybenzeneboronic acid (3 equiv.), powdered K₂CO₃ and Pd(OAc)₂ gave the *title compound* **37** (53 mg, 98%) as colourless crystals, mp 132-133 °C (from cyclohexane); (Found: C, 76.8; H, 4.8; N, 4.0. C₂₂H₁₇NOS requires C, 76.9; H, 5.0; N, 4.1%); λ_{max}(DCM)/nm 232 (log ε 4.06), 245 inf (3.98), 282 (3.82); ν_{max}/cm⁻¹ 3054w (Ar CH), 2962w, 2943w, 2919w, 2840w, 1700w, 1684w, 1608w, 1576m, 1491w, 1478w, 1455w, 1442w, 1430w, 1395w, 1362w, 1316w, 1285m, 1224s, 1171w, 1109w, 1102w, 1090w, 1075w, 1051m, 1030w, 985w, 971w, 940w, 923w, 915w, 883w, 846m, 832w, 791m, 780m, 773m, 757s, 727s; δ_H(300 MHz; CDCl₃) 7.41 (2H, dd, *J* 7.5, 2.0, Ph CH), 7.35-7.22 (8H, m, Ph CH), 7.17 (1H, dd, *J* 8.0, 8.0, Ar CH), 6.83 (1H, dd, *J* 8.4, 2.6, Ar CH), 6.68 (1H, app d, *J* 7.5, Ar CH), 6.60 (1H, dd, *J* 2.0, 2.0, Ar CH), 3.60 (3H, s, OCH₃); δ_C(75 MHz; CDCl₃) 167.6, 164.1, 159.5, 135.6, 135.3, 134.0, 131.0, 129.6 (Ar CH), 128.8 (Ar CH), 128.7 (Ar CH), 128.6 (Ar CH), 128.4 (Ar CH), 128.0 (Ar CH), 123.1 (Ar CH), 115.8 (Ar CH), 113.5 (Ar CH), 55.1 (OCH₃), 1 peak missing; δ_C(75 MHz; DEPT 90, CDCl₃) 129.6 (Ar CH), 128.8 (Ar CH), 128.7 (Ar CH), 128.6 (Ar CH), 128.4 (Ar CH), 128.0 (Ar CH), 123.1 (Ar CH),

115.8 (Ar CH), 113.5 (Ar CH), 1 peak missing; m/z (EI) 344 ($M^+ + 1$, 26%), 343 (M^+ , 100), 342 (35), 328 (3), 326 (3), 312 (8), 298 (3), 272 (2), 240 (3), 208 (3), 197 (3), 178 (2), 165 (6), 155 (7), 121 (3), 77 (4), 62 (2), 51 (2) (Found: M^+ , 343.1045, $C_{22}H_{17}NOS$ requires M , 253.1031).

3,5-Diphenyl-4-(2-methoxybenzene)isothiazole 38

Similar treatment of 4-bromo-3,5-diphenylisothiazole **30** (50 mg, 0.158 mmol) with 2-methoxybenzeneboronic acid (3 equiv.), powdered K_2CO_3 and $Pd(OAc)_2$ gave the *title compound* **38** (53.7 mg, 99%) as colourless crystals, mp 114-115 °C (from pentane); (Found: C, 77.0; H, 4.9; N, 4.0. $C_{22}H_{17}NOS$ requires C, 76.9; H, 5.0; N, 4.1%); λ_{max} (DCM)/nm 235 (log ε 3.19), 279 (3.00); ν_{max}/cm^{-1} 3059w and 3025w (Ar CH), 2835w, 1601w, 1580w, 1559w, 1539w, 1496w, 1479w, 1464w, 1443w, 1433w, 1400w, 1362w, 1265w, 1242m, 1188w, 1161w, 1132w, 1123w, 1105w, 1097w, 1073w, 1046w, 1028m, 973w, 936w, 916w, 906w, 856w, 843w, 809w, 778m, 755s, 746m, 742m, 721w; δ_H (300 MHz; $CDCl_3$) 7.43-7.39 (2H, m, Ar CH), 7.33-7.23 (9H, m, Ar CH), 7.00 (1H, ddd, J 7.5, 1.8, 1.8, Ar CH), 6.87 (1H, dd, J 8.4, 8.4, Ar CH), 6.84 (1H, dd, J 7.8, 7.8, Ar CH), 3.33 (3H, s, OCH_3); δ_C (75 MHz; $CDCl_3$) 168.1, 164.1, 157.3, 136.3, 132.0 (Ar CH), 131.5, 130.7, 129.5 (Ar CH), 128.6 (Ar CH), 128.5 (Ar CH), 128.2 (Ar CH), 128.2 (Ar CH), 127.9 (Ar CH), 127.8 (Ar CH), 123.3, 120.9 (Ar CH), 111.4 (Ar CH), 55.0 (OCH_3); δ_C (75 MHz; DEPT 90, $CDCl_3$) 132.0 (Ar CH), 129.5 (Ar CH), 128.6 (Ar CH), 128.5 (Ar CH), 128.2 (Ar CH), 128.2 (Ar CH), 127.9 (Ar CH), 127.8 (Ar CH), 120.9 (Ar CH), 111.4 (Ar CH); m/z (EI) 344 ($M^+ + 1$, 23%), 343 (M^+ , 100), 342 (24), 328 (5), 312 (20), 207 (7), 197 (5), 165 (9), 155 (8), 121 (4), 77 (6) (Found: M^+ , 343.1031, $C_{22}H_{17}NOS$ requires M , 343.1031).

3,5-Diphenyl-4-(4-tolyl)isothiazole 39

Similar treatment of 4-bromo-3,5-diphenylisothiazole **30** (50 mg, 0.158 mmol) with 4-tolylboronic acid (3 equiv.), powdered K₂CO₃ and Pd(OAc)₂ gave the *title compound* **39** (50.7 mg, 98%) as colourless needles, mp 203-205 °C (from cyclohexane); (Found: C, 80.8; H, 5.3; N, 4.2. C₂₂H₁₇NS requires C, 80.7; H, 5.2; N, 4.3%); λ_{\max} (DCM)/nm 231 (log ε 3.24), 284 (2.94); ν_{\max} /cm⁻¹ 3069w and 3028w (Ar CH), 2922w, 1537w, 1483m, 1443m, 1395m, 1360m, 1273w, 1180w, 1163w, 1109w, 1074w, 1028w, 918w, 907w, 851w, 843w, 818m, 802w, 783m, 775m, 758m, 729s, 716m; δ_{H} (300 MHz; CDCl₃) 7.43-7.40 (2H, m, Ar CH), 7.34-7.22 (8H, m, Ar CH), 7.08, (2H, d, *J* 7.9, Ar CH), 6.97 (2H, d, *J* 6.3, Ar CH), 2.35 (3H, s, CH₃); δ_{C} (75 MHz; CDCl₃) 167.7, 163.7, 137.2, 135.8, 134.2, 131.1, 130.9, 130.4 (Ar CH), 129.3 (Ar CH), 128.9 (Ar CH), 128.7 (Ar CH), 128.7 (Ar CH), 128.6 (Ar CH), 128.3 (Ar CH), 128.0 (Ar CH), 21.3 (CH₃); δ_{C} (75 MHz; DEPT 90, CDCl₃) 130.4 (Ar CH), 129.3 (Ar CH), 128.9 (Ar CH), 128.7 (Ar CH), 128.7 (Ar CH), 128.6 (Ar CH), 128.3 (Ar CH), 128.0 (Ar CH); *m/z* (EI) 328 (M⁺+1, 25%), 327 (M⁺, 100), 326 (49), 312 (22), 250 (7), 223 (4), 208 (3), 191 (6), 179 (37), 165 (11), 156 (8), 155 (8), 149 (5), 121 (3), 103 (3), 77 (6) (Found: M⁺, 327.1072, C₂₂H₁₇NS requires M, 327.1082).

3,5-Diphenyl-4-(3-tolyl)isothiazole 40

Similar treatment of 4-bromo-3,5-diphenylisothiazole **30** (50 mg, 0.158 mmol) with 3-tolylboronic acid (3 equiv.), powdered K₂CO₃ and Pd(OAc)₂ gave the *title compound* **40** (51.2 mg, 99%) as colourless needles, mp 162-163 °C (from pentane); (Found: C, 80.8; H, 5.2; N, 4.3. C₂₂H₁₇NS requires C, 80.7; H, 5.2; N, 4.3%); λ_{\max} (DCM)/nm 237 (log ε 3.89), 283 (3.72); ν_{\max} /cm⁻¹ 3050w (Ar CH), 2955w, 2922w, 2850w, 1605w, 1586w, 1534w, 1490w, 1476w, 1447w, 1442m, 1394w, 1362m, 1291w, 1275w,

1182w, 1172w, 1154w, 1074w, 1030w, 1004w, 986w, 968w, 941w, 921w, 914w, 892w, 849m, 801m, 780m, 772m, 756s, 705s; δ_{H} (300 MHz; CDCl₃) 7.40 (2H, dd, *J* 7.8, 1.7, Ar CH), 7.31-7.21 (8H, m, Ar CH), 7.18-7.08 (2H, m, Ar CH), 6.89-6.87 (2H, m, Ar CH), 2.22 (3H, s, CH₃); δ_{C} (75 MHz; CDCl₃) 167.6, 163.9, 138.1, 135.7, 134.3, 134.0, 131.1 (Ar CH), 131.1, 128.8 (Ar CH), 128.7 (Ar CH), 128.6 (Ar CH), 128.6 (Ar CH), 128.4 (Ar CH), 128.4 (Ar CH), 128.3 (Ar CH), 128.0 (Ar CH), 127.7 (Ar CH), 21.3 (CH₃); δ_{C} (75 MHz; DEPT 90, CDCl₃) 131.1 (Ar CH), 128.8 (Ar CH), 128.7 (Ar CH), 128.6 (Ar CH), 128.6 (Ar CH), 128.4 (Ar CH), 128.4 (Ar CH), 128.3 (Ar CH), 128.0 (Ar CH), 127.7 (Ar CH); *m/z* (EI) 328 (M⁺+1, 27%), 327 (M⁺, 100), 326 (56), 312 (17), 224 (4), 208 (4), 192 (5), 179 (4), 165 (7), 155 (8), 148 (4), 121 (3), 103 (2), 77 (5), 51 (3) (Found: M⁺, 327.1073, C₂₂H₁₇NS requires *M*, 327.1082).

3,5-Diphenyl-4-(2-tolyl)isothiazole 41

Similar treatment of 4-bromo-3,5-diphenylisothiazole **30** (50 mg, 0.158 mmol) with 2-tolylboronic acid (3 equiv.), powdered K₂CO₃ and Pd(OAc)₂ gave the *title compound* **41** (25.4 mg, 49%) as colourless needles, mp 145-146 °C (from cyclohexane); (Found: C, 80.6; H, 5.2; N, 4.3. C₂₂H₁₇NS requires C, 80.7; H, 5.2; N, 4.3%); λ_{max} (DCM)/nm 242 (log ε 3.31), 281 (3.12); ν_{max} /cm⁻¹ 3058w and 3028w (Ar CH), 2919w, 1602w, 1576w, 1559w, 1533w, 1491w, 1476w, 1448m, 1443w, 1396m, 1379w, 1363m, 1269mw, 1205w, 1188w, 1178w, 1158w, 1095w, 1075w, 1072w, 1029m, 1003w, 983w, 969w, 950w, 921w, 909m, 846m, 788m, 779m, 765s, 750s, 733m, 723m; δ_{H} (300 MHz; CDCl₃) 7.43-7.40 (2H, m, Ar CH), 7.32-7.09 (12H, m, Ar CH), 1.87 (3H, s, CH₃); δ_{C} (75 MHz; CDCl₃) 167.4, 163.9, 137.2, 135.7, 133.9, 133.5, 131.2 (Ar CH), 131.1 (Ar CH), 130.5, 128.9 (Ar CH), 128.8 (Ar CH), 128.5 (Ar CH), 128.2 (Ar CH), 128.1 (Ar CH), 128.0 (Ar CH), 126.3 (Ar CH), 19.9 (CH₃) 1 peak missing;

δ_{C} (75 MHz; DEPT 90, CDCl₃) 131.2 (Ar CH), 131.1 (Ar CH), 128.9 (Ar CH), 128.8 (Ar CH), 128.5 (Ar CH), 128.2 (Ar CH), 128.1 (Ar CH), 128.0 (Ar CH), 126.3 (Ar CH), 1 peak missing; m/z (EI) 328 (M⁺+1, 31%), 327 (M⁺, 100), 326 (51), 312 (32), 294 (2), 250 (18), 223 (8), 191 (15), 178 (3), 165 (8), 156 (8), 155 (9), 148 (6), 121 (3), 115 (3), 103 (3), 77 (6), 51(3) (Found: M⁺, 327.1077, C₂₂H₁₇NS requires M, 327.1082). Further elution (hexane-DCM, 7 : 3) gave 3,5-diphenylisothiazole **31** (19.1 mg, 51 %) as colourless needles, mp 80-81 °C (from pentane) identical to that described above.

3,5-Diphenyl-4-(4-chlorobenzene)isothiazole **42**

Similar treatment of 4-bromo-3,5-diphenylisothiazole **30** (50 mg, 0.158 mmol) with 4-chlorobenzeneboronic acid (3 equiv.), powdered K₂CO₃ and Pd(OAc)₂ gave the *title compound* **42** (48.9 mg, 89%) as colourless needles, mp 205-206 °C (from cyclohexane); (Found: C, 72.5; H, 3.9; N, 4.0. C₂₁H₁₄ClNS requires C, 72.5; H, 4.1; N, 4.0%); $\lambda_{\text{max}}(\text{DCM})/\text{nm}$ 237 (log ε 3.25), 280 (2.98); $\nu_{\text{max}}/\text{cm}^{-1}$ 3067w (Ar CH), 2929w, 1598w, 1533w, 1494w, 1479w, 1442w, 1402w, 1394w, 1362w, 1290w, 1273w, 1180w, 1164w, 1113w, 1099w, 1090m, 1074w, 1029w, 1017m, 906w, 825s, 799w, 777m, 760m, 756m, 734m, 721s; δ_{H} (300 MHz; CDCl₃) 7.40-7.20 (12H, m, Ar CH), 7.02 (2H, ddd, *J* 9.6, 2.0, 1.9, Ar CH); δ_{C} (75 MHz; CDCl₃) 167.5, 164.4, 135.4, 133.6, 132.8, 132.5, 131.9 (Ar CH), 130.7, 129.0 (Ar CH), 128.9 (Ar CH), 128.9 (Ar CH), 128.8 (Ar CH), 128.7 (Ar CH), 128.6 (Ar CH), 128.2 (Ar CH); δ_{C} (75 MHz; DEPT 90, CDCl₃) 131.9 (Ar CH), 129.0 (Ar CH), 128.9 (Ar CH), 128.9 (Ar CH), 128.8 (Ar CH), 128.7 (Ar CH), 128.6 (Ar CH), 128.2 (Ar CH); m/z (EI) 349 (M⁺+2, 36%), 348 (M⁺+1, 40), 347 (M⁺, 100), 327 (3), 312 (13), 244 (5), 212 (8), 208 (5), 199 (3), 176 (4), 165 (12), 156 (13), 155 (13), 135 (5), 121 (3), 103 (2), 77 (6), 51 (3)

(Found: M⁺, 347.1531, C₂₁H₁₄ClNS requires M, 347.0535). Further elution (hexane-DCM, 7 : 3) gave *4-(4'-chlorobiphenyl-4-yl)-3,5-diphenylisothiazole* **47** (7.4 mg, 11%) as colourless crystals, mp 224-225 °C (from cyclohexane); (Found: C, 72.4; H, 3.9; N, 4.0. C₂₇H₁₈ClNS requires C, 76.5; H, 4.3; N, 3.3%); $\lambda_{\text{max}}(\text{DCM})/\text{nm}$ 269 (log ε 3.54); $\nu_{\text{max}}/\text{cm}^{-1}$ 3058w (Ar CH), 2926w, 2851w, 1488w, 1479w, 1448w, 1442w, 1395w, 1363w, 1272w, 1183w, 1093m, 1077w, 1030w, 1006w, 922w, 910w, 860w, 841w, 821s, 802w, 780m, 767m, 760m, 742w, 722m; δ_H(300 MHz; CD₂Cl₂) 7.57 (4H, ddd, J 8.7, 2.3, 2.3, Ar CH), 7.50 (2H, ddd, J 8.5, 1.8, 1.8, Ar CH), 7.41 (4H, ddd, J 8.7, 2.3, 2.3, Ar CH), 7.34-7.23 (8H, m, Ar CH), 7.16 (2H, ddd, J 8.5, 1.9, 1.9, Ar CH); δ_C(75 MHz; CD₂Cl₂) 167.9, 164.6, 139.1, 139.1, 136.2, 134.1, 134.0, 133.7, 131.5 (Ar CH), 131.4, 129.2 (Ar CH), 129.2 (Ar CH), 129.1 (Ar CH), 129.1 (Ar CH), 128.8 (Ar CH), 128.5 (Ar CH), 128.4 (Ar CH), 127.2 (Ar CH), 1 peak missing; δ_C(75 MHz; DEPT 90, CD₂Cl₂) 131.5 (Ar CH), 129.2 (Ar CH), 129.2 (Ar CH), 129.1 (Ar CH), 129.1 (Ar CH), 128.8 (Ar CH), 128.5 (Ar CH), 128.4 (Ar CH), 127.2 (Ar CH), 1 peak missing; *m/z* (EI) 426 (M⁺+3, 12%), 425 (M⁺+2, 36), 424 (M⁺+1, 41), 423 (M⁺, 100), 422 (40), 347 (10), 329 (4), 312 (4), 298 (8), 290 (3), 288 (10), 275 (4), 252 (9), 249 (8), 239 (3), 193 (7), 120 (4), 77 (3) (Found: M⁺, 423.0866, C₂₁H₁₄ClNS requires M, 423.0848).

3,5-Diphenyl-4-(3-chlorobenzene)isothiazole 43

Similar treatment of 4-bromo-3,5-diphenylisothiazole **30** (50 mg, 0.158 mmol) with 3-chlorobenzeneboronic acid (3 equiv.), powdered K₂CO₃ and Pd(OAc)₂ gave the *title compound* **43** (45.6 mg, 83%) as colourless cotton like needles, mp 175-176 °C (from cyclohexane); (Found: C, 72.4; H, 3.9; N, 4.0. C₂₁H₁₄ClNS requires C, 72.5; H, 4.1; N, 4.0%); $\lambda_{\text{max}}(\text{DCM})/\text{nm}$ 234 (log ε 3.47), 280 (3.27); $\nu_{\text{max}}/\text{cm}^{-1}$ 3054w (Ar CH),

1597w, 1565w, 1489w, 1468w, 1442w, 1395w, 1361w, 1272w, 1188w, 1119w, 1088w, 1079w, 1072w, 1029w, 999w, 915w, 889w, 843w, 812w, 791m, 778s, 760m, 738s; δ_{H} (300 MHz; CDCl₃) 7.37-7.15 (12H, m, Ar CH), 7.06 (1H, dd, *J* 1.7, 1.7, Ar CH), 6.95 (1H, ddd, *J* 7.5, 1.3, 1.3, Ar CH); δ_{C} (75 MHz; CDCl₃) 167.4, 164.8, 136.0, 135.3, 134.3, 132.6, 130.5, 130.5 (Ar CH), 129.8 (Ar CH), 129.1 (Ar CH), 128.9 (Ar CH), 128.8 (Ar CH), 128.7 (Ar CH), 128.1 (Ar CH), 127.8 (Ar CH) 2 peak missing; δ_{C} (75 MHz; DEPT 90, CDCl₃) 130.5 (Ar CH), 129.8 (Ar CH), 129.1 (Ar CH), 128.9 (Ar CH), 128.8 (Ar CH), 128.7 (Ar CH), 128.1 (Ar CH), 127.8 (Ar CH) 2 peak missing; *m/z* (EI) 349 (M⁺+2, 39%), 348 (M⁺+1, 46), 347 (M⁺, 100) 346 (64), 312 (18), 310 (11), 244 (3), 212 (5), 208 (7), 199 (4), 176 (4), 165 (12), 156 (13), 155 (14), 135 (4), 121 (3), 77 (7), 51 (4) (Found: M⁺, 347.0535, C₂₁H₁₄ClNS requires *M*, 347.0535). Further elution (hexane-DCM, 7 : 3) gave 4-(3'-chlorobiphenyl-3-yl)-3,5-diphenylisothiazole **48** (7.4 mg, 11%) as colourless crystals, mp 143-144 °C (from pentane); (Found: C, 72.5; H, 4.0; N, 4.0. C₂₁H₁₄ClNS requires C, 72.5; H, 4.1; N, 4.0%); λ_{max} (DCM)/nm 233 (log ε 2.79), 325 (3.18); ν_{max} /cm⁻¹ 3068w and 3025w (Ar CH), 1594w, 1565w, 1506w, 1485w, 1473w, 1441w, 1398w, 1388w, 1361w, 1293w, 1250w, 1182w, 1156w, 1100w, 1075w, 1047w, 1029w, 999w, 985w, 968w, 936w, 924w, 914w, 880w, 852w, 828w, 810w, 788m, 777s, 756m, 729s, 708m; δ_{H} (300 MHz; CDCl₃) 7.47-7.07 (14H, m, Ar CH); δ_{C} (75 MHz; CDCl₃) 167.7, 164.3, 142.4, 139.9, 135.7, 134.6, 134.5, 133.8, 131.0, 130.0 (Ar CH), 129.9 (Ar CH), 129.6 (Ar CH), 129.1 (Ar CH), 129.0 (Ar CH), 129.0 (Ar CH), 128.9 (Ar CH), 128.8, (Ar CH), 128.6 (Ar CH), 128.2 (Ar CH), 127.3 (Ar CH), 127.2 (Ar CH), 126.2 (Ar CH), 125.1 (Ar CH); δ_{C} (75 MHz; DEPT 90, CDCl₃) 130.0 (Ar CH), 129.9 (Ar CH), 129.6 (Ar CH), 129.1 (Ar CH), 129.0 (Ar CH), 129.0 (Ar CH), 128.9 (Ar CH), 128.8, (Ar CH), 128.6 (Ar CH), 128.2 (Ar CH), 127.3 (Ar CH), 127.2 (Ar CH), 126.2 (Ar CH), 125.1

(Ar CH); m/z (EI) 425 (M^++2 , 42%), 424 (M^++1 , 45), 423 (M^+ , 100), 422 (39), 387 (3), 347 (5), 310 (5), 309 (3), 298 (7), 288 (9), 284 (4), 275 (4), 252 (10), 239 (4), 192 (6), 186 (7), 165 (3), 155 (3), 120 (5), 103 (3), 77 (9), 51 (4) (Found: M^+ , 423.0864, $C_{27}H_{18}ClNS$ requires M , 423.0848).

3,5-Diphenyl-4-(2-chlorobenzene)isothiazole 44

Similar treatment of 4-bromo-3,5-diphenylisothiazole **30** (50 mg, 0.158 mmol) with 2-chlorobenzeneboronic acid (3 equiv.), powdered K_2CO_3 and $Pd(OAc)_2$ gave the *title compound* **44** (44.5 mg, 81%) as colourless crystals, mp 176-177 °C (from cyclohexane); (Found: C, 72.5; H, 4.0; N, 4.0. $C_{21}H_{14}ClNS$ requires C, 72.5; H, 4.1; N, 4.0%); λ_{max} (DCM)/nm 233 (log ε 3.23), 281 (3.01); ν_{max}/cm^{-1} 3061 (Ar CH), 1597w, 1565w, 1489w, 1468w, 1442w, 1419w, 1410w, 1395w, 1361w, 1272w, 1188w, 1119w, 1089w, 1079w, 1073w, 1029w, 888w, 843w, 815w, 792w, 779s, 761m, 744m, 738s, 729m; δ_H (300 MHz; $CDCl_3$) 7.39-7.17 (12H, m, Ar CH), 7.08-7.07 (1H, m, Ar CH), 6.97 (1H, ddd, J 7.5, 1.4, 1.4, Ar CH); δ_C (75 MHz; $CDCl_3$) 167.4, 164.8, 136.0, 135.3, 134.3, 132.6, 130.6, 130.5 (Ar CH), 129.8 (Ar CH), 129.1 (Ar CH), 128.9 (Ar CH), 128.8 (Ar CH), 128.7, (Ar CH), 128.7 (Ar CH), 128.2 (Ar CH), 127.8 (Ar CH), 1 peak missing; δ_C (75 MHz; DEPT 90, $CDCl_3$) 130.5 (Ar CH), 129.8 (Ar CH), 129.1 (Ar CH), 128.9 (Ar CH), 128.8 (Ar CH), 128.7, (Ar CH), 128.7 (Ar CH), 128.2 (Ar CH), 127.8 (Ar CH), 1 peak missing; m/z (EI) 349 (M^++2 , 38%), 348 (M^++1 , 41), 347 (M^+ , 100), 346 (58), 312 (21), 244 (4), 208 (8), 176 (14), 165 (6), 156 (18), 155 (18), 135 (5), 121 (4), 103 (4), 89 (6), 77 (16), 62 (24), 51 (8) (Found: M^+ , 347.0544, $C_{21}H_{14}ClNS$ requires M , 347.0535). Further elution (hexane-

DCM, 7 : 3) gave 3,5-diphenylisothiazole **31** (7.1 mg, 19%) as colourless needles, mp 80-81 °C (from pentane) identical to that described above.

3,5-Diphenyl-4-(thien-3-yl)isothiazole 45

Similar treatment of 4-bromo-3,5-diphenylisothiazole **30** (50 mg, 0.158 mmol) with 3-thienylboronic acid (3 equiv.), powdered K₂CO₃ and Pd(OAc)₂ gave the *title compound* **45** (50.4 mg, 100%) as colourless needles, mp 186-187 °C (from cyclohexane); (Found: C, 71.3; H, 4.1; N, 4.3. C₁₉H₁₃NS₂ requires C, 71.4; H, 4.1; N, 4.4%); λ_{max} (DCM)/nm 245 (log ε 4.09), 284 (3.80); ν_{max} /cm⁻¹ 3092w and 3057w (Ar CH), 1481w, 1441w, 1418w, 1350w, 1188w, 1072w, 1032w, 856m, 849m, 789s, 775m, 764m, 750s, 722s; δ_H(300 MHz; CDCl₃) 7.47-7.43 (2H, m, Ar CH), 7.37-7.26 (9H, m, Ar CH), 6.95 (1H, dd, *J* 3.0, 1.2, thienyl *H*-2) 6.78 (1H, dd, *J* 5.0, 1.2, thienyl *H*-4); δ_C(75 MHz; CDCl₃) 167.7, 164.1, 135.7, 133.6, 131.0, 129.1, 129.1 (Ar CH), 128.9 (Ar CH), 128.7 (Ar CH), 128.6 (Ar CH), 128.6 (Ar CH), 128.5 (Ar CH), 128.1 (Ar CH), 125.7 (Ar CH), 125.0 (Ar CH); δ_C(75 MHz; DEPT 90, CDCl₃) 129.1 (Ar CH), 128.9 (Ar CH), 128.7 (Ar CH), 128.6 (Ar CH), 128.6 (Ar CH), 128.5 (Ar CH), 128.1 (Ar CH), 125.7 (Ar CH), 125.0 (Ar CH); *m/z* (EI) 320 (M⁺+1, 25%), 319 (M⁺, 100), 318 (63), 286 (10), 285 (4), 272 (4), 242 (3), 216 (3), 184 (16), 171 (15), 159 (3), 143 (5), 139 (5), 121 (3), 103 (2), 84 (3), 77 (7), 62 (3) (Found: M⁺, 319.0488, C₁₉H₁₃NS₂ requires *M*, 319.0489).

3,5-Diphenyl-4-(thien-2-yl)isothiazole 46

Similar treatment of 4-iodo-3,5-diphenylisothiazole **34** (50 mg, 0.138 mmol) with 2-thienylboronic acid (3 equiv.), powdered K₂CO₃ and Pd(OAc)₂ gave the *title compound* **46** (43.6 mg, 99%) as colourless needles, mp 189-190 °C (from

cyclohexane); (Found: C, 71.4; H, 4.0; N, 4.3. $C_{19}H_{13}NS_2$ requires C, 71.4; H, 4.1; N, 4.4%); λ_{max} (DCM)/nm 245 (log ϵ 3.34), 285 (2.96); ν_{max} /cm⁻¹ 3065w (Ar CH), 1601w, 1481w, 1447w, 1441w, 1434w, 1389w, 1360w, 1336w, 1309w, 1283w, 1262w, 1220w, 1186w, 1178w, 1155w, 1092w, 1076w, 1062w, 1033w, 970w, 922w, 916w, 906w, 882w, 848w, 831m, 775m, 752m, 745w, 726m, 720m, 707s; δ_{H} (300 MHz; CDCl₃) 7.51-7.47 (2H, m, Ar CH), 7.37-7.28 (9H, m, Ar CH), 6.97 (1H, dd, *J* 5.1, 3.6, thieryl *H*-4) 6.79 (1H, dd, *J* 3.6, 1.2, thieryl *H*-5); δ_{C} (75 MHz; CDCl₃) 167.9, 165.6, 135.4, 134.4, 130.7, 129.1 (Ar CH), 128.9 (Ar CH), 128.7 (Ar CH), 128.7 (Ar CH), 128.6 (Ar CH), 128.6 (Ar CH), 128.1 (Ar CH), 127.3 (Ar CH), 127.0 (Ar CH), 126.9; δ_{C} (75 MHz; DEPT 90, CDCl₃) 129.1 (Ar CH), 128.9 (Ar CH), 128.7 (Ar CH), 128.7 (Ar CH), 128.6 (Ar CH), 128.6 (Ar CH), 128.1 (Ar CH), 127.3 (Ar CH), 127.0 (Ar CH); *m/z* (EI) 320 (M⁺+1, 27%), 319 (M⁺, 100), 318 (57), 286 (19), 274 (8), 242 (3), 216 (10) 184 (21), 171 (23), 159 (6), 158 (5), 143 (8), 139 (12), 121 (7), 89 (3), 77 (13), 69 (5), 51 (8).

3,4,5-Triphenylisothiazole 17 (typical Stille conditions for coupling at C-4: see Table 3)

A stirred mixture of 3,5-diphenyl-4-iodoisothiazole **34** (30 mg, 0.083 mmol), tributylphenylstannane (40.5 μ l, 0.124 mmol, 1.5 equiv.) and Pd(OAc)₂ (0.9 mg, 5 mol%) in dry and degassed DMF (2 ml) under an argon atmosphere, was heated to *ca.* 100 °C, until no starting material remained (TLC). The mixture was allowed to cool to *ca.* 20 °C, diluted with DCM (15 ml) and washed with H₂O (4 \times 10 ml). The organic layer was separated, dried and absorbed on silica. Chromatography (hexane-DCM, 6 : 4) gave the title compound **17** (25.5 mg, 98%) as colourless needles, mp 210-211 °C (from cyclohexane) identical to that described above.

3,5-Diphenyl-4-(thien-2-yl)isothiazole 46 via Stille coupling at C-4

Similar treatment of 4-iodo-3,5-diphenylisothiazole **34** (30 mg, 0.083 mmol) with tributyl(2-thienyl)stannane (1.5 equiv.) and Pd(OAc)₂ gave the *title compound* **46** (26.2 mg, 99%) as colourless needles, mp 189-190 °C (from cyclohexane) identical to that described above.

3,5-Diphenyl-4-(fur-2-yl)isothiazole 49

Similar treatment of 4-iodo-3,5-diphenylisothiazole **34** (30 mg, 0.083 mmol) with tributyl(2-furyl)stannane (1.5 equiv.) and Pd(OAc)₂ gave the *title compound* **49** (24.6 mg, 98%) as colourless needles, mp 114-115 °C (from cyclohexane); (Found: C, 75.2; H, 4.2; N, 4.6. C₁₉H₁₃NOS requires C, 75.2; H, 4.3; N, 4.6%); λ_{max} (DCM)/nm 247 (log ε 3.18), 280 (2.86); ν_{max} /cm⁻¹ 3125w and 3109w (Ar CH), 1598w, 1525w, 1502w, 1478w, 1447w, 1441w, 1389w, 1352w, 1271w, 1226w, 1181w, 1160w, 1072w, 1031w, 1022w, 1001w, 985w, 940w, 926w, 916w, 885w, 872w, 853w, 842w, 830w, 780m, 767m, 757m, 725s; δ_H(300 MHz; CDCl₃) 7.50-7.46 (2H, m, Ar CH), 7.44 (1H, dd, *J* 2.0, 0.6, furyl *H*-5), 7.42-7.30 (8H, m, Ar CH), 6.38 (1H, dd, *J* 3.3, 1.8, furyl *H*-4) 6.11 (1H, dd, *J* 3.3, 0.6, furyl *H*-3); δ_C(75 MHz; CDCl₃) 168.0, 167.0, 146.2, 142.5 (Ar CH), 135.5, 130.6, 129.3 (Ar CH), 128.8 (Ar CH), 128.8 (Ar CH), 128.3 (Ar CH), 128.2 (Ar CH), 128.2 (Ar CH), 124.1, 111.3 (Ar CH), 111.0 (Ar CH); δ_C(75 MHz; DEPT 90, CDCl₃) 142.5 (Ar CH), 129.3 (Ar CH), 128.8 (Ar CH), 128.8 (Ar CH), 128.3 (Ar CH), 128.2 (Ar CH), 128.2 (Ar CH), 111.3 (Ar CH), 111.0 (Ar CH); *m/z* (EI) 304 (M⁺+1, 23%), 303 (M⁺, 100), 286 (4), 274 (32), 259 (3), 249 (12), 241 (5), 240 (4), 200 (6), 171 (15), 139 (11), 121 (9), 102 (3), 89 (3), 77 (12), 69 (4), 51 (7).